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ABSTRACT 
 
Invasive fungal infections represent nowadays a major public health problem with 
associated high mortality rates. The lack of adequate diagnostic methods, together with the fact 
that many emerging fungal species are resistant to the currently available antifungal agents, 
contributes to the profound impact of these diseases in the health care systems, especially when 
dealing with immunocompromised patients. Taking this into consideration, the development of 
novel diagnostic applications has been considered a critical issue in recent years. We described a 
multiplex PCR-based strategy allowing the identification of eight of the most clinically relevant 
Candida species. The strategy, based on the amplification of fragments from the internal 
transcribed spacer regions of the ribosomal RNA genes, was shown to present both high 
specificity and sensitivity, in addition to other attractive features, including the individual 
discrimination of species present in mixture and the direct identification from clinical specimens, 
characteristics reinforcing the potential clinical application of the method. 
In addition to the need of more satisfactory diagnostic methods, the understanding of the 
host-fungi interaction, namely at the level of host genetic susceptibility, is critical to advance the 
knowledge regarding these infections and, in particular, the individual risk factors predisposing to 
them. Differences in human susceptibility to infectious diseases have been widely described with 
recent examples focusing on genetic variations within genes of the innate immune system, such 
as Toll-like receptors (TLRs), which may alter host-pathogen defence mechanisms, thus affecting 
susceptibility to infectious diseases, and in particular, fungal infections. Taking this into account, 
we developed a simple and rapid method based in the bi-directional PCR amplification of specific 
alleles (Bi-PASA) for genotyping known sequence variants in the TLR genes to be used in the 
forthcoming association studies regarding genetic susceptibility to fungal infections. The 
development of this methodology also allowed us to perform a characterization of the general 
Portuguese population regarding these polymorphisms, that can be used in future association 
studies, besides providing valuable information regarding stratification of patients most at risk of 
infection. 
Following the demonstration of the usefulness of Bi-PASA, we investigated the potential 
association between polymorphisms in the TLR genes and susceptibility to non-invasive forms of 
pulmonary aspergillosis. A significant association was observed between the presence of 
Asp299Gly (TLR4) and chronic cavitary pulmonary aspergillosis. In the same way, this variation 
  viii 
was also linked with fungal colonization in the haematopoietic stem cell transplantation (HSCT) 
setting, suggesting that an abnormal TLR4 extracellular domain may be impairing the recognition 
of the fungus, thus contributing to an increased predisposition to these diseases. However, the 
same polymorphism was previously shown to have a protective role against invasive aspergillosis 
in HSCT patients. Thus, as shown for hyper-inflammatory states, such as atherosclerosis, 
impairments in the production of inflammatory cytokines contributing to disease susceptibility 
may be compensating the effect of the defective TLR4. Furthermore, susceptibility to another 
form of pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, as well as viral infection 
in the HSCT setting, were shown to be associated with T-1237C (TLR9), highlighting the 
divergent function of TLRs in the pathogenesis of these infections. 
A shared susceptibility mechanism involving the T-1237C polymorphism in the promoter 
region of TLR9 was also observed to predispose to the development of non-Hodgkin lymphoma 
(NHL). This disease includes a set of heterogeneous lymphoproliferative malignancies often 
associated with an altered immunological function of the host and chronic inflammatory type of 
infections, in which TLR9 was already shown to play a critical role. The T-1237C polymorphism 
introduces a regulatory site that is trans-activated by the IL-6-dependent transcription factor IL-6 
response element binding protein (IL-6 RE-BP), thus resulting in increased expression of TLR9. 
TLR9 activation of B lymphocytes leads to yet increased gene expression levels and sequentially 
to augmented proliferation rates, as well as higher production of IL-6. This was shown to result in 
a TLR9 activation loop leading to B lymphocyte-specific uncontrolled proliferation, making these 
cells more prone to acquire transforming mutations associated with the development of NHL. 
Besides uncovering a major risk factor for the development of NHL, the presented information 
has important implications on the recent usage of CpG agonists on several therapeutic strategies 
in cancer and autoimmune diseases. 
In summary, we have contributed to show that management of fungal infections, both 
invasive and non-invasive, involves not only the development of more satisfactory diagnostic 
procedures, but also considerable attention that has to be given to individual genetic variants 
that, as we showed, are able to alter susceptibility to these infections. These findings have 
potential relevance for the stratification of patients most at risk, not only of fungal infections, but 
also to diseases of other aetiological natures, whose pathogenesis share common 
signalling/activation pathways such as those presented by the TLRs. 
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RESUMO 
 
 Actualmente, as infecções fúngicas invasivas representam um importante problema de 
saúde pública, sendo responsáveis por elevadas taxas de mortalidade. A falta de métodos de 
diagnóstico adequados, associada à resistência que muitas das espécies fúngicas emergentes 
apresentam aos antifúngicos disponíveis, contribui para um profundo impacto destas doenças, 
especialmente no caso dos doentes imunocomprometidos. Tendo em consideração estes 
aspectos, o desenvolvimento de novas metodologias de diagnóstico tem sido encarado como 
uma necessidade prioritária. Neste sentido, desenvolveu-se uma nova estratégia, baseada em 
PCR multiplex, que permite a identificação de oito das espécies de Candida mais relevantes em 
termos clínicos. Este método, baseado na amplificação de fragmentos dos genes de RNA 
ribossomal, apresenta uma elevada especificidade e sensibilidade. A sua potencial aplicação 
clínica é ainda reforçada por outras características, nomeadamente a discriminação individual de 
espécies presentes em co-infecção e a identificação directa a partir de espécimes clínicos. 
 Juntamente com a necessidade de desenvolvimento de métodos de diagnóstico mais 
satisfatórios, a compreensão da interacção hospedeiro-fungo, nomeadamente ao nível da 
susceptibilidade genética humana, é essencial para o avanço do conhecimento destas infecções. 
Diferenças na susceptibilidade humana a doenças infecciosas têm sido descritas, associadas 
nomeadamente a variações em genes do sistema imunológico inato, como os receptores “Toll-
like” (TLRs). Recentemente, verificou-se que estas variações podem alterar os mecanismos de 
defesa antimicrobianos, afectando a susceptibilidade a doenças infecciosas. Assim, tendo em 
conta estes aspectos, desenvolvemos um método simples e rápido para genotipar polimorfismos 
nos genes TLR, de forma a aplicá-lo na análise da susceptibilidade a infecções fúngicas nos 
estudos de associação subsequentes. O desenvolvimento desta metodologia permitiu ainda a 
caracterização da população Portuguesa em relação a estes polimorfismos, dados que poderão 
ser usados em estudos futuros, para além de fornecer informação pertinente acerca da 
estratificação de pacientes com maior risco de desenvolverem infecções. 
Após a demonstração da utilidade da técnica de Bi-PASA, investigámos a potencial 
associação entre polimorfismos nos genes TLR e a susceptibilidade a formas não-invasivas de 
aspergilose pulmonar. De acordo com os resultsdos obtidos, observou-se uma associação entre 
a presença de Asp299Gly (TLR4) e a aspergilose pulmonar crónica cavitária. De forma idêntica, 
verificou-se uma associação entre o mesmo polimorfismo e a colonização fúngica em doentes 
  x 
sujeitos a transplante de células estaminais hematopoiéticas (HSCT), sugerindo que um domínio 
extracelular anómalo de TLR4 pode limitar o reconhecimento do fungo, contribuindo para uma 
maior predisposição para estas doenças. Contudo, a mesma variação apresentou um papel 
protector em relação a aspergilose invasiva, sugerindo que uma redução na produção de 
citocinas pró-inflamatórias poderá equilibrar o defeito anterior, tal como foi anteriormente 
demonstrado para estados patológicos de hiper-inflamação, como a aterosclerose. 
Adicionalmente, demonstrámos que o polimorfismo T-1237C (TLR9) estava associado a uma 
maior susceptibilidade a aspergilose broncopulmonar alérgica, uma outra forma de aspergilose 
pulmonar, assim como a infecções virais em pacientes HSCT, realçando a função divergente dos 
TLRs na patogénese destas doenças. 
 Um mecanismo de susceptibilidade partilhado envolvendo o polimorfismo T-1237C 
surgiu também como predispondo para o desenvolvimento de linfoma não-Hodgkin (NHL). Este 
inclui um conjunto de doenças linfoproliferativas, frequentemente associadas a alterações 
imunológicas do hospedeiro e infecções associadas a respostas inflamatórias crónicas, nas quais 
já foi descrito um papel importante de TLR9. O polimorfismo T-1237C introduz um local de 
regulação que é trans-activado por um factor de transcrição dependente de IL-6, resultando 
numa elevada expressão de TLR9. A activação deste receptor em linfócitos B leva a um aumento 
da sua expressão genética e, consequentemente, a taxas de proliferação mais elevadas, assim 
como à produção excessiva de IL-6. Estas alterações, juntamente com uma activação persistente 
de TLR9, culminam numa proliferação descontrolada dos linfócitos B, tornando estas células 
mais susceptíveis à aquisição de mutações transformantes associadas com o desenvolvimento 
de NHL. Para além de termos evidenciado o polimorfismo T-1237C como um factor de risco 
para o desenvolvimento de NHL, a informação resultante apresenta ainda importantes 
implicações no uso, recentemente preconizado, de agonistas de TLR9 em diversas estratégias 
terapêuticas, nomeadamente cancro e doenças autoimunes. 
 Em resumo, demonstrámos que a abordagem das infecções fúngicas deve abranger não 
só um interesse particular no fungo, através do desenvolvimento de métodos de diagnóstico 
mais eficazes, mas também uma atenção considerável às variações genéticas individuais que, 
como demonstrámos, podem modular a susceptibilidade a estas infecções. Os resultados aqui 
apresentados têm uma potencial relevância na estratificação de pacientes com maior risco para 
infecções fúngicas, bem como doenças de outras etiologias, cuja patogénese partilha vias 
comuns de sinalização/activação, como as apresentadas pelos TLRs. 
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OBJECTIVES AND OUTLINE OF THE THESIS 
 
 The work presented throughout this dissertation was developed in the context of the 
projects “Recognition mechanisms of pathogen-associated molecular patterns: implications in 
susceptibility to infections relevant to public health” (funded by Fundação Calouste Gulbenkian, 
Programa de Apoio à Prevenção e Rastreio de Doenças Infecciosas e Oncológicas Socialmente 
Relevantes) and “A multidisciplinary study of invasive fungal infections in immunosuppressed 
patients: host susceptibility to fungi versus fungi resistance to drugs” (funded by Fundação para 
a Ciência e Tecnologia). 
 The fact that most of the currently available diagnostic procedures for invasive fungal 
infections are still not satisfactory contribute to the high mortality rates associated to these 
infections. Additionally, the lack of knowledge concerning the host-pathogen interaction, namely 
at the level of host genetic susceptibility, led us to propose the following objectives for this thesis: 
(1) to develop molecular methodologies with potential clinical and epidemiological application in 
the identification of relevant fungal pathogens, providing an alternative to currently available 
procedures (2) to study the potential associations between polymorphisms in TLR genes and 
susceptibility to fungal infection, both invasive and non-invasive forms, and (3) to elucidate the 
functional impact of the abovementioned polymorphisms in the mechanisms of disease 
susceptibility. 
The present dissertation is organized in 8 different chapters, with the last chapter 
consisting of the reference list. Chapter 1 consists of a general introduction, presenting a review 
of the current knowledge on the host-pathogen interaction, with particular emphasis on the innate 
immune response and its genetic variants, and the manner(s) in which they may predispose to 
infectious disease, more specifically fungal infection. 
In chapter 2, the work “Multiplex PCR identification of eight clinically relevant Candida 
species” is presented, focusing on the development of a rapid, simple and effective PCR-based 
methodology to specifically detect and identify clinically relevant Candida species. The developed 
method presents several advantages over currently available diagnosis procedures, including high 
specificity and sensitivity, as well as reduced time required for identification. Altogether, these 
characteristics point to a highly advantageous method with potential application in both clinical 
diagnosis and epidemiological studies. 
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In chapter 3, the work “Study of disease-relevant polymorphisms in the TLR4 and TLR9 
genes: a novel method applied to the analysis of the Portuguese population” is presented, 
showing the development of a genotyping method based on allele-specific PCR and its application 
in the characterization of the general Portuguese population regarding polymorphisms in TLRs, 
thus providing valuable information that can be potentially used to stratify risk patients with 
increased susceptibility to infection. 
In chapter 4, the work “Polymorphisms in Toll-like receptor genes and susceptibility to 
pulmonary aspergillosis” is presented, showing a case-control association study between 
polymorphisms in TLRs and susceptibility to non-invasive forms of pulmonary aspergillosis. The 
findings presented in this chapter reinforce the importance of innate immunity, and in particular 
genetic variations in TLR genes, in the pathogenesis of different forms of pulmonary aspergillosis. 
In chapter 5, the work “Polymorphisms in Toll-like receptor genes and susceptibility to 
infections in allogeneic stem cell transplantation” is presented, describing the results of a case-
control association study regarding the contribution made by polymorphisms in TLRs to 
susceptibility to fungal and/or viral infection in patients undergoing haematopoietic stem cell 
transplantation (HSCT). The results presented in this chapter highlight the divergent function of 
TLRs in the pathogenesis of opportunistic infections, in particular in the HSCT setting. 
In chapter 6, the work “Risk of developing non-Hodgkin lymphoma associates with the T-
1237C polymorphism in the TLR9 promoter” is presented, illustrating the role of a TLR9 
polymorphism in the development of non-Hodgkin lymphoma (NHL). This line of research was 
initiated during the studies depicted in chapter 5, upon the observation that this polymorphism 
was highly prevalent in NHL patients. In particular, data is presented regarding the functional 
impact of this polymorphism and the molecular mechanisms underlying increased susceptibility 
to NHL, suggesting an important role for TLR9 in the development of this malignancy. 
In chapter 7, concluding remarks are presented bringing together Chapter 2, 3, 4, 5 and 
6 in the context of the initially proposed objectives. In particular, the importance of TLR 
polymorphisms in susceptibility/resistance to fungal infections, as well as the significance of the 
shared pathways affected by these polymorphisms and their role in the predisposition to diseases 
of other aetiologies, is highlighted. Furthermore, future perspectives in the research regarding 
genetic susceptibility to fungal infection are depicted, particularly in what refers to the further 
clarification of the role of TLR polymorphisms in the normal function of the innate immune 
system and its impact in disease susceptibility. 
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1.1 INVASIVE FUNGAL INFECTIONS 
 
Fungi are ubiquitous organisms present in the environment that are virtually unavoidable 
by humans. This omnipresence has led to the evolution of innate and acquired host defence 
antifungal mechanisms in multicellular organisms. Indeed, few fungal species regularly cause 
invasive disease in humans, and most of these act as opportunistic pathogens in individuals with 
specific immune defects; there are about 20 fungal species that cause >99% of human fungal 
infections, although about 600 different species have been reported as a cause of infection in 
man. Fungal infections are classified broadly into four groups: invasive, life-threatening infections 
(e.g. aspergillosis and candidiasis), mucosal infections, skin infections and allergic infections (e.g. 
asthma and chronic sinusitis). 
 
1.1.1 EPIDEMIOLOGY 
 
The availability of modern and sophisticated medical care to prolong and improve the 
lives of severely debilitated individuals has become increasingly common in the modern health 
care systems. Ironically, such medical advances have resulted in a group of patients more 
vulnerable to fungal infections. Such patients include those who receive immunosuppressive 
chemotherapy that produces prolonged neutropenia, such as bone-marrow or solid-organ 
transplant recipients (Fridkin and Jarvis, 1996). In fact, the number of life-threatening invasive 
fungal infections has risen dramatically over the last 20 years. Data collected in a 12-year study 
showed that the frequency of invasive fungal infections as judged after death by unselected 
autopsies had raised approximately 14 fold (Groll et al., 1996). More recently, this trend was 
confirmed in a hospital population-based study performed in several European countries for over 
28 months. In particular, this study reported that invasive infection caused by Candida species 
ranged from 0.20 to 0.38 per 1,000 admissions and from 3.0 to 4.4 per 100,000 patient days 
(Tortorano et al., 2004). 
Candida species are currently the fourth most common agent of all hospital-acquired 
bloodstream infection in the USA; such infections are increasingly significant causes of morbidity 
and with an estimated mortality of 25-38% (Wenzel and Edmond, 2001). Although sentinel 
surveillance studies in the 1980s indicated that the overall incidence of Candida bloodstream 
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infections increased among patients in hospital intensive care units (Banerjee et al., 1991), the 
incidence of infections caused by C. albicans, historically the most common agent in these 
infections, significantly decreased in this population in the 1990s (Trick et al., 2002). During the 
same period, a significant increase in C. glabrata bloodstream infections occurred (Trick et al., 
2002). In fact, recent epidemiologic trends indicate a shift towards infections by non-albicans 
Candida species (Tortorano et al., 2004). In addition, Aspergillus species and previously 
uncommon fungi that often have little susceptibility to current antifungal agents are also 
becoming increasingly significant causes of fungal infection; the crude mortality from invasive 
aspergillosis is approximately 85% (Marr et al., 2002). 
Several factors might be responsible for the emergency of non-albicans Candida 
species and other fungi. In addition to the abovementioned increase in the population of 
profoundly immunosuppressed patients who are at very high risk for developing infections, also 
the increased use of antifungal agents might select for non-albicans species that exhibit 
decreased susceptibility to these agents. For example, prophylactic use of fluconazole has been 
associated with the emergence of C. krusei and C. glabrata (Wingard et al., 1991; Wingard et al., 
1993) and empiric or prophylactic use of amphotericin B has been linked with the emergence of 
C. lusitaniae and C. glabrata (Nguyen et al., 1996). Finally, increased recognition of the 
importance of non-albicans Candida species, not only because species distribution has changed 
in recent years, but also due to differences in susceptibility to antifungal agents, might lead to 
increased efforts to speciate Candida isolates in clinical microbiology laboratories. 
 
1.1.2 DIAGNOSIS 
 
Medical mycology has faced an enormous obstacle for decades: timely and accurate 
diagnosis of invasive fungal infections. Identification of Candida species has traditionally required 
isolation of the infecting organism from a normally sterile site, such as blood, peritoneal fluid or 
intravenous lines. In addition, these infections are difficult to diagnose because cultures are often 
negative or they become positive late in the disease; indeed, blood cultures were reported to be 
negative in up to 50% of all autopsy-proven cases of invasive candidiasis in such patients 
(Berenguer et al., 1993). If a culture is positive, accurate identification of the agent is laborious 
and time-consuming, relying on macroscopic and microscopic morphologic characteristics, 
biochemical tests, and serotyping. Regarding Candida, perhaps the most convenient and popular 
  5 
methods for species identification are tests based on carbohydrate assimilation and/or enzyme 
detection which are commercially available in an assortment of different formats. 
Physicians and microbiologists have recognized these limitations and have been 
intensively developing alternative diagnostic methods for decades. Some of these have been very 
successful, such as the Cryptococcus and Histoplasma antigen detection methods, which have 
become diagnostic standards due to their availability and diagnostic performance (Powderly et 
al., 1994; Wheat et al., 1986). Some, on the other hand, have been frustrating and laid to rest, 
such as Candida antibodies and metabolites (Reiss et al., 2000; Verweij et al., 1998). 
Newer molecular methods employing polymerase chain reaction (PCR) technology offer 
the potential for more rapid and specific identification of fungal pathogens compared to 
traditional phenotypic methods, although not yet standardized or readily available in most clinical 
laboratories. Also, large clinical trials to determine the sensitivity and specificity of such molecular 
tests are nonexistent. Several PCR-based techniques have been developed using amplification of 
target DNA (Burgener-Kairuz et al., 1994; Crampin and Matthews, 1993; Fujita et al., 1995; 
Miyakawa et al., 1992). Fungal ribosomal genes are common DNA targets in PCR-based 
procedures for the identification of fungi at the species level. The highly variable sequences of 
internal transcribed spacer regions ITS1 and ITS2 flanked by the relatively conserved coding 
regions of 18S, 5.8S and 28S nuclear rRNA genes have been used in various PCR-based formats 
for the identification of clinically relevant yeasts (Chang et al., 2001; Elie et al., 1998; Fujita et 
al., 1995; Williams et al., 1995). There are now a multitude of techniques that include both 
quantitative and qualitative methods, real-time PCR, and combinations of PCR and enzyme-linked 
immunosorbent assay (ELISA), which can be carried out on blood and other human fluids 
(McMullan et al., 2008; Schabereiter-Gurtner et al., 2007). 
The detection of fungal cell wall components, such as galactomannan and β-glucan is 
also very promising. The galactomannan assay for Aspergillus species has shown repeated good 
performance in a variety of settings and hosts, and widespread use is already ongoing 
(Meersseman et al., 2008; Steinbach et al., 2007; Woods et al., 2007). In addition, detection of 
β-glucan showed very good sensitivity and specificity, but more important, it showed an 
impressive negative predictive value (Odabasi et al., 2004). 
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1.1.3 THERAPY 
 
For many years, the antifungal arsenal consisted only of amphotericin B desoxycholate 
(D-AmB) and 5-fluorocytosine (5-FC). However, side effects with the use of D-AmB are common, 
occurring in 50-90% of the cases, and are principally nephrotoxicity-related. Therapeutic 
alternatives only emerged with the clinical development of fluconazole and itraconazole in the late 
1980s. Although inactive against filamentous fungi, fluconazole has been shown to be as 
effective as amphotericin B in the treatment of candidaemia in non-neutropenic patients (Phillips 
et al., 1997; Rex et al., 1994). However, the use of fluconazole may be inappropriate for the 
empirical treatment of suspected fungal infection, because prior exposure, as treatment or 
prophylaxis, is associated with the appearance of resistant strains of Candida species, and 
because of its lack of activity against moulds (Pappas et al., 2004). Itraconazole, on the other 
hand, has a wider spectrum than fluconazole, being active against yeasts and moulds, with some 
known exceptions (Johnson et al., 1998). 
In the past 10 years, we have witnessed a significant expansion in antifungal drug 
research, which is reflected by the introduction of the lipid formulations of amphotericin B and 
the development of novel echinocandin derivatives (anidulafungin, caspofungin and micafungin) 
and improved antifungal triazoles (posaconazole, ravuconazole and voriconazole). Presently, 
amphotericin B, fluconazole and itraconazole are the cornerstones of treatment of invasive fungal 
infections. However, the use of other antifungal agents such as caspofungin is starting to look 
promising. Caspofungin has been shown to be as effective as amphotericin B, although better 
tolerated since its side effects are uncommon and usually mild (Mora-Duarte et al., 2002). At 
present, it is used mainly as a second-line agent in patients with life-threatening invasive Candida 
or Aspergillus infections unresponsive to first-line therapy. 
Increased awareness among physicians, improved blood culture techniques and 
molecular diagnostic tools, together with the advent of high-resolution imaging techniques have 
had considerable impact on improving the clinical diagnosis of invasive fungal infections. In 
addition, major progress has been made in harmonizing disease definitions, in defining 
paradigms for antifungal intervention, and in designing and implementing clinical trials. Despite 
these advances, however, invasive fungal infections remain difficult to diagnose and to manage, 
and there is a continuing and urgent need for improved diagnosis, treatment, and prevention. 
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1.2 INNATE IMMUNITY TO FUNGAL PATHOGENS 
 
 Host defence mechanisms influence the manifestation and severity of fungal infections 
such that the clinical forms of the disease often depend on the immune response of the host. 
The innate immune response is focused mainly on physically eliminating the fungus, mostly by 
phagocytosis, while the adaptive response reacts specifically to, and neutralizes the pathogen 
and maintains a memory of it for safer and faster elimination on subsequent encounters. 
However, fungi also play a key role in the host-pathogen interaction. The pathogenesis of fungal 
infections involves several virulence factors that allow fungal survival and persistence in the host, 
eventually leading to tissue damage. Some virulence factors are of obvious importance, such as 
the structures through which fungi adhere to host tissues and the extracellular matrix, production 
of phospholipases, proteases and elastases that cause tissue damage and impairment of host 
defences, the ability to switch metabolic pathways that are required for intracellular survival, 
thermotolerance that allows dissemination to visceral organs, and the ability to survive in different 
forms and to reversibly switch from one to another during infection (Hogan et al., 1996; Latge, 
2001). 
 
1.2.1 THE INNATE IMMUNE SYSTEM 
 
The immune system of vertebrates consists of two inter-related components, the innate 
and adaptive responses, which are jointly required for the resolution of most infections. The 
innate immune response, phylogenetically conserved and present in almost all multicellular 
organisms, is the first line of host defence and is responsible for immediately recognizing and 
countering microbial invasion (Hoffmann et al., 1999). This arm of the immune system is 
comprised mainly of phagocytic cells such as macrophages and neutrophils, which can ingest 
and kill the invading pathogens. These cells can also instruct the adaptive immune response 
about the nature of the pathogenic challenge through cytokine and chemokine production, 
expression of costimulatory molecules and presentation of microbial antigens to lymphocytes 
leading to the development of a highly specific immune response that is tailored to combat the 
individual microorganism. 
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The specificity of the adaptive immune response relies on the recognition of peptide 
antigens using antigen receptors expressed on the surface of lymphocytes. In order to provide 
specific recognition of a wide range of potential antigens, lymphocytes are able to rearrange their 
receptor genes through random somatic mutation generating a selection of receptors that best 
recognize the microbial antigens. Engagement of these receptors by the cognate antigen triggers 
clonal expansion of the lymphocyte and further production of antigen-specific antibodies. By 
contrast, the innate immune response is based on a limited number of evolutionarily conserved 
germline-encoded receptors, the pattern recognition receptors (PRRs), which recognize highly 
conserved microbial structures, enabling the host to rapidly recognize a broad range of 
pathogens (Janeway and Medzhitov, 2002). These microbial components, known as pathogen-
associated molecular patterns (PAMPs), are essential for the survival of the microorganisms and 
are therefore difficult to alter. Furthermore, innate immunity also constantly monitors host 
internal environment to detect any endogenous changes which might be caused by tissue injury, 
apoptosis, viral infection and/or tumour formation (Medzhitov and Janeway, 2002). 
PRRs can be broadly categorized into three groups based on their cellular localization – 
serum/tissue fluid, membrane or cytoplasm – and further subdivided into related families based 
on structure and/or function. Leukocytes use these receptors to recognize pathogens either 
directly or indirectly, whereby distinct opsonic receptors recognize PRR-coated pathogens. 
Recognition also occurs in vacuoles after microbe uptake, or in the cytoplasm, which is required 
for the detection of intracellular pathogens. During infection in vivo, microbial recognition is likely 
to occur through multiple interactions at multiple sites and to involve many receptors. 
Following recognition, some PRRs promote microbial uptake through the actin-dependent 
process of phagocytosis. Microbial killing then occurs in the resultant vacuole (known as the 
phagosome) and is achieved through various mechanisms, such as lowering of the phagosomal 
pH, production of reactive oxygen intermediates (ROIs) and release of hydrolytic enzymes and 
toxic metabolites into the phagosome. Microbial recognition and uptake also leads to the 
induction of an inflammatory response – including the production of cytokines and chemokines – 
which activates and recruits other cells to the site of infection, leading ultimately to the initiation 
of the adaptive arm of the immune response. 
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1.2.2 PATHOGEN RECOGNITION BY TOLL-LIKE RECEPTORS 
 
The field of innate immunity was guided to its present era of accelerated development 
mostly due to the discovery of a class of membrane PRRs known as Toll-like receptors (TLRs). In 
1996, the Drosophila protein Toll, originally identified as a transmembrane receptor required for 
the establishment of dorso-ventral polarity in the developing fly embryos (Belvin and Anderson, 
1996; Hashimoto et al., 1988), was shown to be required for flies to mount effective antifungal 
responses (Lemaitre et al., 1996). 
In the Drosophila, stimulation of Toll by the secreted Spätzle factor, a ligand of Toll, 
activates the cytoplasmic serine/threonine kinase Pelle via the adaptor protein Tube. Spätzle is a 
polypeptide precursor that requires proteolytic cleavage by serine proteases for activation. 
Activation of Pelle promotes degradation of the ankyrin-repeat protein Cactus, a homologue of 
mammalian inhibitor of nuclear factor-kappa B (NF-κB) IκB which associates with the NF-κB 
family transcription factor Dorsal in the cytoplasm. Once Cactus is degraded in response to the 
Toll-mediated signal, Dorsal is free to translocate to the nucleus, where it regulates transcription 
of specific target genes (Belvin and Anderson, 1996). 
The signalling pathway of Drosophila Toll shows remarkable similarity to the mammalian 
interleukin (IL)-1 pathway, which leads to the activation of NF-κB, a transcription factor 
responsible for many aspects of inflammatory and immune responses. Indeed, the cytoplasmic 
domains of Drosophila Toll and the mammalian IL-1 receptor are highly conserved and referred 
to as the Toll/IL-1 receptor (TIR) domain. In addition to the presence of homologous cytoplasmic 
TIR domains, both receptors can induce NF-κB activation and signal through homologous protein 
kinases – Pelle and IL-1 receptor-associated kinase (IRAK) (Anderson, 2000; Belvin and 
Anderson, 1996). Based on this similarity, it was proposed that the Toll-mediated pathway could 
be involved in regulating immune responses (Belvin and Anderson, 1996). This was clearly 
demonstrated in a study involving mutant flies lacking individual components of the Toll-mediated 
pathway, i.e., Toll, Spätzle, Tube or Pelle (Lemaitre et al., 1996). The mutant flies demonstrated 
a striking defect in immune responses, being highly susceptible to fungal infection owing to a lack 
of expression of the antifungal peptide drosomycin. 
A year after the discovery of the role of the Drosophila Toll in the host defence against 
fungal infection, a mammalian homologue, now known as TLR4, was identified (Medzhitov et al., 
1997). Subsequently, a family of proteins structurally related to Drosophila Toll was also 
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identified. The human TLR family is known to consist of at least 12 members that differ from 
each other in ligand specificities, expression patterns and presumably, in the target genes they 
can induce (Chuang and Ulevitch, 2000; Du et al., 2000; Medzhitov et al., 1997; Rock et al., 
1998; Takeuchi et al., 1999; Zhang et al., 2004). Besides their cytoplasmic TIR domain, these 
receptors are structurally characterized also by the presence of a leucine-rich repeat (LRR) 
domain in their extracellular portion, composed of 19-25 tandem LRR motifs, each of which is 
24-29 amino acids in length. It was imagined that the LRR domain of the TLR would form a 
horseshoe structure with the ligand binding to the concave surface. However, the three-
dimensional structure of the human TLR3 has recently been elucidated, and its structure 
suggests a somewhat different model in which negatively charged dsRNA is more likely to bind 
the outside convex surface of TLR3 (Choe et al., 2005). 
TLRs are expressed on various immune cells, including macrophages, dendritic cells 
(DCs), B cells, specific subsets of T cells, and even on nonimmune cells such as fibroblasts and 
epithelial cells. Expression of TLRs is not static but is rather rapidly modulated in response to 
pathogens, a variety of cytokines and environmental stresses. Furthermore, TLRs may be 
expressed either extra- or intracellularly; while certain TLRs (TLR1, -2, -4, -5 and -6) are expressed 
on the cell surface, others (TLR3, -7, -8 and -9) are found almost exclusively in intracellular 
compartments such as endosomes, and their ligands, mainly nucleic acids, require 
internalization to the endosome before signalling is possible. 
The engagement of TLRs by microbial components triggers the activation of signalling 
cascades, leading to the induction of genes involved in antimicrobial host defence (Akira and 
Takeda, 2004). After ligand binding, TLRs dimerize and undergo conformational changes 
required for the recruitment of TIR domain-containing adaptor proteins to the cytoplasmic portion 
of the TLRs through homophilic interaction of their TIR domains. There are four adaptor 
molecules, namely myeloid differentiation factor 88 (MyD88), TIR-associated protein 
(TIRAP)/MyD88-adaptor-like (MAL), TIR domain-containing adaptor protein inducing interferon 
(IFN)-β (TRIF)/TIR domain-containing molecule 1 (TICAM1) (Oshiumi et al., 2003) and TRIF-
related adaptor molecule (TRAM). The differential responses mediated by distinct TLR ligands can 
be explained in part by the selective usage of these adaptor molecules. MyD88 and TRIF are 
responsible for the activation of distinct signalling pathways, leading to the production of 
proinflammatory cytokines and type I IFN, respectively (Figure 1). 
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MyD88 is critical for the signalling from all TLRs except TLR3. Upon TLR stimulation, 
MyD88 associates with their TIR domains and recruits IRAK-4 and IRAK-1 through a homophilic 
interaction of their death domains. In TLR2 and TLR4 signalling, another adaptor, TIRAP/MAL, is 
required for recruiting MyD88 to the receptor (Fitzgerald et al., 2001; Horng et al., 2002; 
Yamamoto et al., 2002). After IRAK-1 associates with MyD88, it is phosphorylated by the 
activated IRAK-4 and subsequently associates with tumour necrosis factor receptor (TNFR)-
associated factor 6 (TRAF6), which acts as an ubiquitin ligase (Li et al., 2002). TRAF6, together 
with an ubiquitination enzyme complex, catalyzes the formation of a polyubiquitin chain on 
TRAF6 itself and on inhibitor of NF-κB kinase complex (IKK)-γ/NF-κB essential modulator 
(NEMO) (Deng et al., 2000). The ubiquitinated TRAF6 then associates with a complex composed 
of transforming growth factor (TGF)-β-activated kinase 1 (TAK1) and the TAK1-binding proteins 1 
and 2 (TAB1 and TAB2) (Wang et al., 2001a). TAK1 is able to activate the inhibitor of the IKK. 
IKK-mediated phosphorylation of IκB leads to its degradation, allowing NF-κB to translocate to 
the nucleus and promote the transcription of multiple proinflammatory genes. In addition, TAK1 
can also activate mitogen-activated protein (MAP) kinases, such as c-Jun N-terminal kinases 
(JNKs) and p38, leading to the activation of activator protein 1 (AP-1) to regulate the expression 
of proinflammatory cytokine genes (Sato et al., 2005). In addition to NF-κB and AP-1, the 
transcription factor IFN regulatory factor 5 (IRF-5) also regulates the expression of cytokine 
genes, binding to potential IFN-stimulated response element (ISRE) motifs present in the 
promoter regions of these genes (Takaoka et al., 2005). 
Stimulation with TLR3, -4, -7, -8 and -9 ligands, but not TLR2 ligands, induces type I IFN 
production via a MyD88-independent pathway in addition to proinflammatory signals. The activity 
of this pathway leads to DC maturation, expression of costimulatory molecules and type I IFN 
secretion, inducing an antiviral state in various cells in addition to modulating the development of 
adaptive immunity (Kaisho and Akira, 2001). This MyD88-independent pathway is initiated by 
another TIR domain-containing adaptor, TRIF (Hoebe et al., 2003; Yamamoto et al., 2003). TRIF 
recruitment to the TIR domain of TLR4 is specifically coordinated by TRAM (Fitzgerald et al., 
2003b; Yamamoto et al., 2003). TRIF then interacts with receptor-interacting protein 1 (RIP1), a 
kinase responsible for the activation of NF-κB (Meylan et al., 2004). On the other hand, TRIF is 
also able to activate the TRAF family member-associated NF-κB activator (TANK) binding kinase 1 
(TBK1) via TRAF3 (Hacker et al., 2006; Oganesyan et al., 2006). TBK1 is known to comprise a 
family of inducible IκB kinases that are able to directly phosphorylate IRF-3 and/or IRF-7 
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(Fitzgerald et al., 2003a; Sharma et al., 2003). Phosphorylated IRF-3 and IRF-7 form 
homodimers, translocate into the nucleus, and bind to the ISRE motifs, resulting in the 
expression of a set of IFN-inducible genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The TLR signalling pathway. Adapted from Akira et al., 2006. 
 
 
1.2.3 TOLL-LIKE RECEPTORS IN ANTIFUNGAL INNATE IMMUNITY 
 
The observation that Toll-deficient Drosophila were highly susceptible to fungal infection 
led to the assumption that mammalian TLRs also participated in antifungal immunity. In fact, 
several PAMPs located in the cell wall or on the cell surface of fungi are recognized by TLR2 or 
TLR4. The T helper (Th) 1 response is critical in protection against fungi; although TLR-mediated 
signals mostly induce Th1-directed responses, activation of TLR2 is less inflammatory and 
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favours the development of the Th2 response through the induction of IL-10 (Agrawal et al., 
2003). Indeed, in vivo infection experiments using mutant mice suggest differential roles of TLR2 
and TLR4 in fungal infection. TLR4-deficient mice showed increased susceptibility to 
disseminated Candida infection, whereas TLR2-deficient mice showed increased resistance 
(Netea et al., 2004). The higher susceptibility displayed by TLR4-/- mice was mediated through 
decreased release of the chemokines keratinocyte-derived chemokine (KC) and macrophage 
inflammatory protein 2 (MIP2), and through impaired recruitment of neutrophils at the site of 
infection. In contrast, production of proinflammatory cytokines such as TNF and IL-1β were only 
marginally influenced, whereas the candidal killing capacity of TLR4-defective phagocytes was 
normal. On the other hand, the TLR2-mediated anti-inflammatory signals leading to IL-10 release 
and generation of positive cluster of differentiation 4 and 25 (CD4+ CD25+) T regulatory cells were 
shown to be responsible for the increased resistance of TLR2-deficient mice to disseminated 
Candida infection. These data demonstrate that C. albicans is able to use TLR2 recognition and 
signalling to induce immunosuppression through IL-10 production, thereby escaping host 
defence. 
A similar escape mechanism from the host defence is also observed in A. fumigatus 
infection. TLR2 and TLR4 have been implicated in host defence against A. fumigatus and A. 
niger, a non-pathogenic Aspergillus species. Germination of conidial forms is an important 
mechanism for initiating and establishing an infection, and both Aspergillus conidia and hyphae 
stimulate cytokine production via TLR2 in mice (Mambula et al., 2002), whereas only conidia are 
capable of stimulating murine macrophages via TLR4 (Netea et al., 2003). Thus, the phenotypic 
switch from conidia to hyphae, resulting in the release of IL-10 through TLR2-dependent 
mechanisms, impairs the cellular immune response necessary for the Aspergillus clearance. This 
indicates that activation of specific cell surface receptors during germination may allow 
Aspergillus to counteract host defences, contributing to its survival. In addition, Aspergillus 
conidia and hyphae induce NF-κB translocation and release of TNF-α in a TLR2- and TLR4-
dependent manner, which is associated with chemokine production and influx of neutrophils and 
monocytes into infected tissues. Mice lacking functional chemokine receptor 1 (CCR1) are much 
less efficient at blocking tissue invasion and have increased susceptibility to infection (Gao et al., 
1997). In the same way, neutrophil recruitment is severely impaired in mice lacking both 
functional TLR2 and TLR4, but is less impaired in single TLR2- or TLR4-deficient mice, suggesting 
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that both receptors are required for an optimal immune response to Aspergillus (Meier et al., 
2003). 
In addition to TLR2 and TLR4, the role of TLR9 in the host defence against Candida was 
also investigated (Bellocchio et al., 2004a). While no increased susceptibility of TLR9-/- mice to 
disseminated candidiasis has been observed, the fungal burden in the organs of deficient 
animals tended to be lower than that in control mice. However, in contrast to TLR2-/- mice, TLR9-/- 
animals produced less IL-12 and more IL-10 and IL-4 than control mice. It is not know why this 
shift towards an anti-inflammatory cytokine profile, known to be deleterious for the anticandidal 
host defence, did not result in such effect on the outcome of the infection. 
With regard to the specific signalling pathways activated by these fungi, responses to A. 
fumigatus have been reported to occur in a MyD88-independent manner (Marr et al., 2003). By 
contrast, mediation of macrophage phagocytosis and killing of C. albicans requires the 
involvement of MyD88, suggesting that murine macrophages might use different pathways that 
are specific to different types of pathogenic fungi. In addition, the MyD88-dependent signal 
transduction pathway is required for adaptive Th1 cell-mediated resistance to both C. albicans 
and A. fumigatus (Bellocchio et al., 2004a). It has also been demonstrated that dectin-1, a non-
classical C-type lectin expressed mainly in myeloid cells and that binds β-glucans, can collaborate 
with TLR2 in response to yeast to elicit a strong inflammatory response via recruitment of the 
protein tyrosine kinase Syk (Gantner et al., 2003; Rogers et al., 2005; Underhill et al., 2005). 
However, although β-glucan is presented during C. albicans yeast growth, it is not presented 
during filamentous growth. As a consequence, dectin-1-mediated antimicrobial defences are not 
effective against filaments, which may explain why they are more virulent. 
 
1.2.4 ANTIFUNGAL EFFECTOR MECHANISMS 
 
The antifungal effector functions of phagocytes include killing and growth inhibition of 
fungi, as well as pathways to oppose fungal invasion, including effects on dimorphism and 
phenotypic switching. The optimal restriction of fungal growth occurs through a combination of 
oxidative and complementary non-oxidative mechanisms, the latter consisting of degranulation 
and intra- or extracellular release of effector molecules, defensins and neutrophil cationic 
peptides, and iron sequestration (Romani, 2004). Enzymes such as the nicotinamide adenine 
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dinucleotide phosphate (NADPH) oxidase and the inducible nitric oxide synthase (iNOS) initiate 
the oxidative pathways known as respiratory burst, in which toxic ROIs are produced, the nature 
of which depends on the pathogens and the type of phagocytic cell. ROIs damage fungi by 
inducing protein modifications, nucleic acid breaks and lipid peroxidation (Mansour and Levitz, 
2002). In retaliation, fungi have evolved strategies to selectively inhibit the respiratory burst 
through production of ROI scavengers, such as catalase, mannitol and melanin (Hamilton and 
Holdom, 1999). Some fungi have also developed various mechanisms or putative virulence 
factors to evade phagocytosis and survive inside macrophages (Brandhorst et al., 1999; Ibata-
Ombetta et al., 2003; Tucker and Casadevall, 2002; Woods, 2003). In fact, macrophages serve 
as a protected environment in which the dimorphic fungi, such as Histoplasma capsulatum, a 
classical example of a successful intracellular fungal pathogen, multiplies and disseminates from 
the lungs to other organs (Woods, 2003). 
Several components of the innate immune response, such as complement, collectins 
and antibodies, are essential in promoting opsonization and recognition of fungi by various 
receptors. In fact, humoral factors are known to be essential in the innate immune response to 
Aspergillus. Resting conidia, germinating conidia and hyphae are potent activators of the 
complement cascade and induce deposition of complement components upon the fungal 
surface. In the alveolar fluid, pulmonary surfactant protein A (SP-A) and D (SP-D) enhance 
chemotaxis, binding, phagocytosis and oxidative killing of Aspergillus (Madan et al., 1997). These 
C-type lectins also agglutinate Aspergillus conidia, thereby immobilizing the pathogen. These 
immune mechanisms are also present in the host response to C. albicans. The fungus activates 
complement by the classical and alternative pathways with deposition on the cell fungal surface, 
facilitating the recruitment of phagocytes to infected tissues and enhancing their anticandidal 
activity. However, despite the importance of these humoral factors in experimental systems, the 
predisposing factor for the vast majority of patients with invasive disease appears to be 
phagocytic dysfunction rather than defects in humoral immunity (Andrews and Sullivan, 2003). 
Antibodies contribute to the activation of the complement system by fungi (Kozel, 1996) 
and complement is essential for antibody-mediated protection (Han et al., 2001). Studies with 
Cryptococcus neoformans have shown that the high levels of carbon dioxide in the lungs favour 
capsule formation, impairing phagocytosis in the absence of capsular antibodies (Syme et al., 
1999). These antibodies can alter the conformation of the capsule and so directly favour binding 
and phagocytosis of the yeasts (Taborda and Casadevall, 2002). However, antibodies have 
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disparate biological effects in fungal infections, with both protective and non-protective antibodies 
being induced during infection (Bromuro et al., 2002). Complement, antibodies and collectins not 
only fulfil the requirement of a first line of defence against fungi, but also have an impact on the 
inflammatory and adaptive immune responses through several mechanisms, including regulation 
of cytokine secretion and expression of costimulatory molecules by phagocytes (Sato et al., 2003; 
Vecchiarelli et al., 2002). 
Cell surface and secreted PRRs mediate the development of appropriate Th responses. 
In this regard, pentraxin 3 (PTX3) has been shown to be required for the prompt handling of 
Aspergillus conidia by alveolar macrophages. In fact, PTX3-deficient mice are susceptible to 
invasive pulmonary aspergillosis due to defective recognition of conidia by alveolar macrophages 
and DCs, and lack of development of appropriate Th1 responses (Garlanda et al., 2002). These 
deleterious effects can be reversed by treatment with purified PTX3, which restores both 
phagocytic and conidiocidal activities (Garlanda et al., 2002). 
 
 
1.3 GENETIC SUSCEPTIBILITY TO INFECTIOUS DISEASES 
  
During the past century, differences in human susceptibility to several infectious diseases 
have been described, the best known example being malaria. Individuals who are heterozygous 
for haemoglobin S (HbS) are protected against infection by Plasmodium falciparum, while those 
homozygous for HbS have sickle cell anaemia (Allison, 1954). Although malaria provides an 
example of a genetic variant resulting in decreased susceptibility to an infectious disease, there is 
also evidence that genetic variants can lead to an increased occurrence of infections. In fact, a 
study comparing the causes of death among adopted children with those of either their biological 
or adoptive parents led to the conclusion that children had an increased risk of death resulting 
from infections when their biological parents also prematurely died from the same cause 
(Sorensen et al., 1988). This study, which effectively separated genetic and environmental 
confounders, confirmed the substantial genetic effect involved in susceptibility to infection. 
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1.3.1 HUMAN GENETICS: EXPLORING SUSCEPTIBILITY TO DISEASE 
  
Although humans are identical at most of the 3 billion base pairs in their genome, inter-
individual variation is present in approximately 0.01% of the genome (Goldstein and Cavalleri, 
2005). Since the mutation rate in mammalian genomes is low (10-9 per bp per year), most inter-
individual variations are inherited. The most common type of human genetic variation is the 
single nucleotide polymorphism (SNP), in which two alternative bases occur at appreciable 
frequency (>1%) within a population. Another type of genetic mutation is the variable number of 
tandem repeats (VNTR), consisting of repeats of sequences ranging from a single to thousands of 
base pairs (Ellegren, 2004). Since the number of repeats varies among individuals, VNTRs have 
been widely used as genetic markers. Once markers have been typed, two main approaches can 
be used to analyse them: single marker analysis or haplotype analysis, the latter referring to the 
arrangement of two or more alleles on the same chromosome. In addition, certain SNPs or VNTR 
alleles, or both, may be linked together so that non-functional polymorphisms can be used as 
genetic markers of functionally important mutations.  
Only 1.5% of SNPs are thought to be located in the coding region of a gene, with the 
functions of nearly all SNPs that are located outside gene coding or regulatory regions being 
unknown. These genetic variations, however, are not randomly distributed within the genome, but 
rather depend on the particular genomic region, as well as on selective pressure (Zhang and 
Hewitt, 2003). Hence, it is reasonable to speculate that genes of the innate immune system may 
represent a major source of variability regarding susceptibility to infectious diseases. Although 
natural immunity ensures survival of the species as a whole, individuals themselves are not likely 
to be immunocompetent to all pathogens, and individual differences in susceptibility to specific 
pathogens are quite common.  
The traditional approach to study a genetic trait is to narrow down the genetic region of 
interest by use of linkage analysis, followed by fine mapping and association studies (Bochud et 
al., 2007). Linkage and association studies are based on the same underlying principle; once a 
mutation occurs on a particular chromosome, it is subsequently transmitted to offspring together 
with nearby loci. This association is broken down at each successive generation by 
recombination. When two loci are close enough on the same chromosome that their alleles 
cosegregate when passed on to the next generation, the two loci are said to be in linkage 
disequilibrium. 
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Whereas linkage and association studies can both be carried out in families, only 
association studies can be performed in unrelated cases and controls. Thus, association studies 
are able to capitalize on all meiotic recombination events in a population, rather than only those 
in the families studied; because of this, association signals are localized to small regions of the 
chromosome containing only a single to a few genes, enabling rapid detection of the actual 
disease susceptibility gene.  Also, association studies allow the identification of disease genes 
with only modest increases in risk, a severe limitation in linkage studies. Due to these 
advantages, association studies can identify multiple interacting disease genes and their 
respective pathways, providing a comprehensive understanding of the aetiology of disease. On 
the other hand, the power to detect association between genetic variation and disease is a 
function of several factors, including the frequency of the risk allele or genotype, the relative risk 
conferred by the disease-associated allele or genotype, the correlation between the genotyped 
marker and the risk allele, sample size, disease prevalence and heterogeneity, and genetic 
heterogeneity of the sampled population. 
 
1.3.2 POLYMORPHISMS IN TOLL-LIKE RECEPTORS 
 
Several genetic variants have been described within the pattern recognition molecules 
involved in innate immunity, affecting their functional activity. A major example is that of 
mannose-binding lectin (MBL) deficiency, one of the most common human immunodeficiencies. 
MBL is a member of the collectin family, which also includes SP-A and SP-D (Epstein et al., 
1996; Holmskov, 2000). Since it was first reported, MBL deficiency has been consistently 
associated with increased susceptibility to many infectious diseases, particularly when adaptive 
immunity is compromised (e.g., in early childhood (Koch et al., 2001; Summerfield et al., 1997) 
or following chemotherapy (Eisen and Minchinton, 2003; Peterslund et al., 2001)). Five 
functional SNPs exist within the MBL2 gene, each affecting serum levels of the protein. Three 
polymorphisms are present at codons 52, 54 and 57 encoding for variant alleles D, B, and C, 
respectively, which dramatically reduce functional MBL levels by impairing the assembly of MBL 
monomers into functional oligomers (Garred et al., 2003). Two additional SNPs at positions -551 
(H/L), and -221 (X/Y) in the 5’ flanking region of the MBL2 gene affect transcriptional activity of 
the basal-promoter complex and reduce levels of circulating MBL (Madsen et al., 1995). Of 
these, two promoter haplotypes, HY, which is associated with high levels of MBL, and LX, which 
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is associated with low MBL levels, appear to be the most important. Through the combination of 
structural and promoter polymorphisms, MBL concentrations can vary considerably in apparently 
healthy individuals (Steffensen et al., 2000).  
The impact of genetic variants in the functional activity of innate immunity components 
was further elucidated by the discovery of two cosegregating polymorphisms of the human TLR4 
gene – Asp299Gly and Thr399Ile. These SNPs were described to be present at a substantially 
higher proportion among individuals hyporesponsive to inhaled lipopolysaccharide (LPS) (Arbour 
et al., 2000). Epithelial cells derived from these individuals were unable to mediate LPS signalling 
in vitro, both in the homozygous and heterozygous state. Moreover, similar findings were 
observed with alveolar macrophages, with the wild-type allele being able to reverse the 
phenotype. Finally, THP-I cells transfected with the mutated human TLR4 gene also displayed 
lower responses to administered LPS. Because these SNPs are located within the extracellular 
domain of TLR4, the impact is most likely caused by impairment in ligand recognition. However, 
functional studies indicated that the Asp299Gly genotype might have a greater functional impact 
compared with the Thr399Ile genotype (Arbour et al., 2000). 
 This report was followed by a series of studies investigating the potential impact of these 
SNPs on the incidence and course of infectious diseases (Cook et al., 2004). One of them 
confirmed an association of these SNPs with the incidence of septic shock during infections with 
Gram-negative bacteria (Lorenz et al., 2002b). These data were, in part, supported by studies 
investigating the distribution of Gram-negative pathogens in critically ill patients in a surgical 
setting (Agnese et al., 2002). In contrast, two studies investigating the influence of the TLR4 
SNPs on the incidence of sepsis after surgery (Lorenz et al., 2001b) and severity of inflammatory 
response syndrome (Child et al., 2003) have failed to detect a significant correlation. One 
problem may be that the aetiology of sepsis is heterogeneous and that TLR4 SNPs would only be 
predicted to alter susceptibility to Gram-negative infections. In addition, several rare TLR4 coding 
variants were markedly over-represented in patients with systemic meningococcal infections 
caused by the Gram-negative organism Neisseria meningiditis, supporting the notion that rare, 
rather than common, variants of TLR4 may be associated with susceptibility to infectious disease 
(Smirnova et al., 2003). 
 The Asp299Gly polymorphism has also been correlated with a reduced risk for carotid 
artery atherosclerosis (Kiechl et al., 2002) and acute coronary events (Ameziane et al., 2003; 
Boekholdt et al., 2003). Individuals with this polymorphism have lower concentrations of 
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circulating proinflammatory cytokines such as IL-6, fibrinogen and soluble vascular cell adhesion 
molecule 1 (VCAM-1). These molecules have well described functions in inflammation, which in 
turn is associated with atherosclerotic progression, plaque rupture and consequent vessel 
occlusion. The finding that the heat shock protein HSP60 from Chlamydia pneumonia can 
activate TLR4 signalling (Sasu et al., 2001) might be of particular relevance to vascular disease 
because this protein has been found in atherosclerotic lesions. Recognition of HSP60 by human 
TLR4 might exacerbate the inflammatory component of atherosclerosis in individuals harbouring 
C. pneumonia, whereas those with the Asp299Gly polymorphism might be partially protected by 
decreased recognition/signalling. In addition, the association between TLR4 function and 
atherosclerosis is consistent with findings showing that TLR4 mRNA and protein are more 
abundant in plaques in atherosclerotic lesions than in unaffected vessels (Xu et al., 2001). 
A non-synonymous SNP within a conserved part of the C-terminal region of human TLR2 
(Arg753Gln) was also reported (Lorenz et al., 2000). As shown for Asp299Gly and Thr399Ile, this 
polymorphism led to a decreased activation of transfected HEK293 cells by TLR2 ligands in vitro 
(Lorenz et al., 2000). Arg753Gln has been associated with susceptibility to tuberculosis (Ogus et 
al., 2004). Interestingly, it also appeared to protect from the development of late stage Lyme 
disease, perhaps due to a reduced signalling via TLR2 (Schroder et al., 2005). In contrast, there 
was no apparent association between this SNP and disease or mortality attributable to S. aureus 
infection (Moore et al., 2004). 
 Besides TLR4 and TLR2, other TLRs were studied with regard to their genetic variation 
and association to disease susceptibility. Two variants of human TLR9 were identified within the 
promoter region, as well as a number of rare non-synonymous SNPs within the coding sequence 
(Lazarus et al., 2003). An association of one of the promoter SNPs – T-1237C – with asthma 
was reported, whereas no significant results were found regarding the other variants. In addition, 
a role for this polymorphism in Crohn’s disease was also reported (Torok et al., 2004). Previous 
suggestions were made that TLR9 signalling mediated the anti-inflammatory effects of probiotics 
in murine experimental colitis model (Rachmilewitz et al., 2004), thus differences in TLR9 
expression could very well be involved in Crohn’s disease pathogenesis. More recently, the same 
SNP was also reported to be involved in the susceptibility to atopic eczema and alterations in 
TLR9 expression were considered to underlie this putative association (Novak et al., 2007). 
A common dominant stop codon occurring within the human TLR5 gene (392STOP) has 
also been described (Hawn et al., 2003), abolishing flagellin-induced signal transduction, thus 
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underlying increased susceptibility to pneumonia caused by Legionella pneumophila, a flagellated 
bacterium. 
In addition to polymorphisms in TLRs, genetic variants have also been identified within 
molecules involved in TLR signalling, namely CD14. Specifically, two SNPs within the promoter 
region of CD14 were reported, and there is evidence that one of them is related to the incidence 
and mortality of septic shock (Schroder et al., 2003). Several reports also emphasized the 
importance of these SNPs for cardiovascular diseases as well, possibly reflecting the 
inflammatory nature of atherosclerosis pathology (Arroyo-Espliguero et al., 2004). 
 
1.3.3 SUSCEPTIBILITY TO FUNGAL INFECTIONS 
  
During the past two decades, invasive fungal infections have emerged as a major threat 
to immunocompromised hosts. Prolonged neutropenia, T cell depletion, graft-versus-host disease 
(GvHD) and the administration of immunosuppressive agents all contribute to the high incidence 
of these infections (Maury et al., 2001). Both host and pathogen factors determine the clinical 
outcome of invasive fungal infections and, whereas some variation may be attributable to fungi 
and environmental variables, it is probable that the host genetic background also plays a 
significant role. Genetic analysis of innate immune genes may identify a subset of patients most 
vulnerable to fungal infections and this ability to predict susceptibility to specific infections can be 
directed towards the design of novel therapeutic approaches to protect these patients. 
 Although the immunological status of the host is probably the main determinant of the 
clinical presentation of fungal infections, very little is known about the genetic susceptibility to 
these infections. Recent evidence has focused on proteins such as SP and MBL, which have 
been identified as key players that strengthen the innate immune response by interacting with 
pathogens and with immune effector cells (van de Wetering et al., 2004). More specifically, an 
important role for SP-A and MBL in host defence against A. fumigatus was described (Madan et 
al., 2005). In fact, the presence of the common mutation in codon 52 of MBL (variant D) has 
been shown to significantly associate with chronic cavitary pulmonary aspergillosis (CCPA) (Vaid 
et al., 2007), which is in accordance to earlier findings that reported a significant correlation of 
the same mutation with the other form of chronic pulmonary aspergillosis, CNPA (Crosdale et al., 
2001). Unlike CCPA patients, no significant association between variant D of MBL and 
susceptibility to allergic bronchopulmonary aspergillosis (ABPA) was observed. However, a 
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polymorphism in the intronic region of MBL has been shown to associate with ABPA, and 
elevated plasma MBL levels and activity, as well as eosinophilia were suggested as the underlying 
mechanisms of susceptibility to this form of allergic aspergillosis (Kaur et al., 2006). 
Allele variants in SP-A2, one of the genes encoding for functional SP-A, have been 
associated with increased susceptibility to both ABPA and CCPA (Vaid et al., 2007). One of those 
variants, a non-synonymous SNP, results in the substitution of an alanine residue for a proline 
residue in the collagen domain of SP-A2, in which proline residues provide structural stability to 
the triple helical collagen structures. Although the precise effect of this change on functionality of 
SP-A is not yet known, patients with ABPA carrying the mutant allele showed a marked increase 
in total immunoglobulin E (IgE) antibodies and peripheral eosinophilia as well as decreased lung 
performance (Saxena et al., 2003). The occurrence of distinct genotype combinations of SP-A2 
and MBL2 in CCPA and ABPA patients suggests that these combinations, along with other 
genetic factors, may confer distinct immune status to the host and may thus be partially 
responsible for the pathogenesis of these diverse clinical entities caused by the same fungus. 
The dominance of either Th1 or Th2 pathways directly correlates with the outcome and 
severity of fungal infections. Polymorphisms in cytokine genes have been associated with CCPA 
and could explain the devastating consequences of the disease in otherwise healthy individuals 
without any obvious immune defect. Sambatakou and colleagues showed that the presence of a 
particular allele variant in the gene encoding for IL-15 was found to be common among CCPA 
patients, leading them to produce high levels of the cytokine (Sambatakou et al., 2006). IL-15 
promotes a non-protective Th2 response, thus rendering these individuals more susceptible to 
aspergillosis. In contrast, a mutation in the promoter region of the gene encoding for TNF-α, 
known to underlie elevated levels of the cytokine, is less common in CCPA patients (Sambatakou 
et al., 2006). Accordingly, in vitro studies have demonstrated that TNF-α enhances specific 
phagocytic activity against conidia by pulmonary alveolar macrophages and augments the 
neutrophil damage of Aspergillus hyphae (Roilides et al., 1998b). 
 The inheritance of a specific allele variant in the promoter region of the gene encoding for 
IL-10 was also associated with the development of CCPA (Sambatakou et al., 2006). The 
presence of this variant correlates with reduced IL-10 production by lymphocytes, suggesting that 
the regulatory role of IL-10 upon pulmonary immune responses and in suppressing acute 
inflammation seems to be crucial to the development of CCPA. In contrast, non-CCPA 
aspergillosis appears to associate with genotypes leading to high levels of IL-10 (Sambatakou et 
  23 
al., 2006). Accordingly, a significant relationship between the high IL-10 production genotype and 
both colonization with A. fumigatus and ABPA in patients with cystic fibrosis was also reported 
(Brouard et al., 2005). In addition, elevated IL-10 concentrations have been reported to associate 
with the development of invasive aspergillosis (IA) (Roilides et al., 2001). 
 Since allogeneic haematopoietic stem cell transplantation (HSCT) dramatically impairs 
various layers of the innate immune response, subtle defects in immune recognition could 
become clinically significant. In fact, in healthy individuals, the redundancy of the different innate 
immune pathways could camouflage a subtle defect. A specific IL-10 promoter haplotype has 
been shown to have a protective impact upon the development of IA after allogeneic HSCT 
regardless of human leukocyte antigen (HLA) disparity or GvHD, although no correlation with IL-
10 serum levels was studied (Seo et al., 2005). In accordance, Sainz and colleagues also 
reported a protective role for the presence of a specific genotype of the IL-10 promoter in the 
pathogenesis of IA after allogeneic HSCT, suggesting that a differential production of IL-10 may 
alter the risk for IA in haematological patients (Sainz et al., 2007a). 
 The primary effector cells of the innate immune response against A. fumigatus are 
alveolar macrophages that can induce production of inflammatory cytokines such as TNF-α 
(Taramelli et al., 1996). In addition to TNF-α, lymphotoxin (LT)-α is also considered a pivotal 
mediator of inflammatory responses to infections with fungi (Bazzoni and Beutler, 1996). 
However, polymorphisms in the genes encoding for these cytokines were not associated with the 
development of IA, results consistent with the similarity in plasma cytokine levels between the 
groups of patients analyzed (Sainz et al., 2007b). Also, no correlation was found between IA and 
polymorphisms in the TNF receptor type 2 (TNFR2) gene, known to disrupt effective signalling. In 
contrast, a polymorphic site in the promoter region of TNFR2 was shown to predispose to IA 
(Sainz et al., 2007b). It is possible that this variant sequence in the promoter region of TNFR2 
decreases its expression, thus explaining the increased susceptibility to IA. However, functional 
studies are yet required to fully understand the impact of this VNTR in the pathogenesis of IA. 
In addition to cytokine genes, polymorphisms within PRRs were also correlated with 
increased susceptibility to IA after allogeneic HSCT. In fact, polymorphisms in MBL-associated 
serine protease 2 (MASP-2), known to lead to deficiencies in the MBL pathway, were shown to be 
predictive factors for IA after allogeneic HSCT (Granell et al., 2006). Additionally, Kesh and 
colleagues have shown that a particular polymorphism in TLR1 (Arg80Thr) or the simultaneous 
occurrence of SNPs in both TLR1 and TLR6 (Asn248Ser and Ser249Pro, respectively) 
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predisposed to IA after allogeneic HSCT (Kesh et al., 2005). Interestingly, in the same study, no 
association with the clinically relevant TLR4 polymorphisms was observed. 
Because TLR4 has been implicated in the host defence against Candida species (Netea 
et al., 2002), common genetic variants within this receptor were proposed to underlie increased 
susceptibility to Candida infections. In fact, Van der Graaf and colleagues demonstrated that 
Asp299Gly and the co-segregated Thr399Ile polymorphisms of TLR4 were associated with an 
increased risk for Candida bloodstream infection (Van der Graaf et al., 2006). In addition, an 
increased IL-10 production upon Candida stimulation was proposed as the underlying 
mechanism for this increased susceptibility. A similar tendency was also observed for patients 
who had recovered from candidaemia. These data were corroborated by the fact that IL-10 has 
been previously shown to inhibit the action of human monocytes against C. albicans (Roilides et 
al., 1998a). Also, in mice with disseminated candidiasis, the absence of IL-10 potentiated 
antifungal immunity by increasing the production of proinflammatory cytokines, leading to 
reduced fungal growth (Del Sero et al., 1999). The notion that TLR4 induces a more 
proinflammatory cytokine profile, while TLR2 has a more pronounced anti-inflammatory bias 
(Netea et al., 2004) may suggest that a defective TLR4-mediated signalling indirectly leads to a 
suppressive Th2 cytokine response through unaffected TLR2-induced IL-10 production, thus 
resulting in increased susceptibility to disseminated Candida infection. 
Previous work reported no association between TLR4 polymorphisms and vaginal 
colonization by C. albicans (Morre et al., 2002). The fact that these patients were colonized 
rather than having signs of active infection was suggested as underlying the lack of association. 
In addition, specific T cell-mediated immunity is the main line of defence against mucosal 
candidiasis, whereas the innate immune response, in which TLR4 recognition is crucial, is 
responsible for defence against disseminated candidiasis.  
Although a great deal is known about the nature, ligands, interactions, genetic variants 
and functions of the innate immune receptors, innate immune recognition remains very complex, 
as it has to protect the host against a highly diverse microbial world. Their ability to discriminate 
among different classes of microorganisms, as well as modified host cells, remains poorly 
understood. Undoubtedly, the future study of these receptors will give more insights into innate 
immune cell biology and may provide alternative targets for the modulation of cell function for the 
treatment of infectious and non-infectious diseases. 
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ABSTRACT 
 
Invasive fungal infections, specifically candidaemia, constitute major public health 
problems with high mortality rates. Therefore, in the last few years, the development of novel 
diagnostic methods has been considered a critical issue. Herein we describe a multiplex PCR 
strategy allowing the identification of 8 clinically relevant yeasts of the Candida genus, namely C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, C. lusitaniae and 
C. dubliniensis. This method is based on the amplification of two fragments from the ITS1 and 
ITS2 regions by the combination of 2 yeast-specific and 8 species-specific primers in a single 
PCR reaction. Results from the identification of 231 clinical isolates are presented pointing to the 
high specificity of this procedure. Furthermore, several Candida isolates were identified directly 
from clinical specimens also attesting to the method’s direct laboratory application. The results 
from the multiplex reactions with other microorganisms that usually co-infect patients also 
confirmed its high specificity in the identification of Candida species. Moreover, this method is 
simple and presents a sensitivity of approximately 2 cells per ml within 5 hours. Furthermore, it 
allows discrimination of individual Candida species within polyfungal samples. This novel method 
may therefore provide a clinical diagnostic procedure with direct applicability. 
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INTRODUCTION 
 
Invasive fungal infections represent a public health problem of major importance (Beck-
Sague and Jarvis, 1993; Fridkin and Jarvis, 1996). In particular, candidaemia has been reported 
within similar rates in different countries, ranging from 0.20-0.38 per 1,000 admissions and 
from 3.0-4.4 per 100,000 patient days (Tortorano et al., 2004). This emergence is often 
associated with human immunodeficiency virus (HIV) or to advanced medical and surgical 
interventions that compromise patient immunity, e.g., bone-marrow or solid-organ transplants, 
aggressive chemotherapy and broad application of antifungal agents (Fridkin and Jarvis, 1996). 
In fact, nosocomial fungal bloodstream infections are an increasingly significant cause of 
morbidity, with an estimated mortality of 25-38% (Wenzel and Edmond, 2001). Candida albicans 
is the most common and clinically relevant pathogen of the genus. However, there has been a 
significant trend towards the emergence of species other than C. albicans, with a particular 
increase in C. glabrata frequency (Diekema et al., 2002; Pfaller and Diekema, 2002; Tortorano et 
al., 2004) and to a lesser extent, C. parapsilosis and C. tropicalis (Kao et al., 1999). In addition, 
given that several non-albicans Candida species are intrinsically resistant to common antifungal 
agents, accurate identification methods are critical for the establishment of appropriate antifungal 
therapy (Kao et al., 1999). 
The cornerstone of laboratory detection of bloodstream fungal infections, including 
candidaemia, remains direct examination and conventional blood culture. However, these 
methods are of limited clinical value since there are negative outcomes in as high as 50% 
autopsy-confirmed cases of candidaemia. In addition, cultures may only become positive late in 
the infection (Berenguer et al., 1993). Furthermore, most phenotypic methods of identification 
used in clinical laboratories are often time-consuming and may lead to inconclusive results. For 
example, phenotypic tests such as VITEK and ID32C systems require several days before 
biochemical reactions can be interpreted (Fenn et al., 1994). On the other hand, molecular 
approaches have the potential to detect candidaemia with increased sensitivity and specificity. 
Buchman et al. were the first to demonstrate that detection of C. albicans in clinical specimens 
was possible by PCR amplification of the lanosterol-alpha-demethylase (L1A1) gene (Buchman et 
al., 1990). Other PCR-based techniques have been developed using amplification of target DNA, 
providing alternative strategies for the diagnosis and identification of fungal pathogens (Burgener-
Kairuz et al., 1994; Crampin and Matthews, 1993; Fujita et al., 1995; Miyakawa et al., 1992). 
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Fungal ribosomal genes are common DNA targets in PCR-based procedures for the identification 
of fungi at the species level. The highly variable sequences of internal transcribed spacer regions 
ITS1 and ITS2 flanked by the relatively conserved coding regions of 18S, 5.8S and 28S nuclear 
rRNA genes have been used in various PCR-based formats for the identification of medically 
important yeasts (Chang et al., 2001; Elie et al., 1998; Fujita et al., 1995; Williams et al., 1995). 
Even though these molecular techniques are highly sensitive and specific, their limited 
applicability has been the need for expensive equipment not readily accessible to many 
diagnostic laboratories. 
We describe a rapid and simple multiplex PCR-based method able to specifically identify 
8 clinically relevant Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. 
krusei, C. guilliermondii, C. lusitaniae and C. dubliniensis) based on the amplification of 
particular DNA fragments of the ITS1 and ITS2 regions. The method combines two yeast-specific 
primers and eight Candida species-specific primers in a single PCR reaction yielding two 
amplicons of different sizes for each species. In addition, this method provides the following 
advantages over currently available techniques: (1) it can be used to test several clinical samples, 
including blood culture bottles and urine samples, (2) whole yeast cells may be employed directly 
in the PCR mixture, (3) it is highly specific and sensitive, with a detection limit of 2.15±0.25 
cells/ml, (4) it has the potential to discriminate individual Candida species in polyfungal 
infections to a maximum ratio of 1:10, and (5) it presents good reproducibility among different 
PCR thermal cyclers and within different laboratories. Altogether, the features of this method 
point to a novel and highly advantageous application in the identification of Candida species in 
both clinical diagnosis and epidemiological studies. 
 
 
MATERIALS AND METHODS 
 
Yeast and bacterial strains. A total of 231 yeast isolates (90 Candida albicans, 61 C. 
parapsilosis, 25 C. tropicalis, 19 C. krusei, 18 C. glabrata, 13 C. guilliermondii and 5 C. 
lusitaniae) were recovered from clinical specimens in two Portuguese medical institutions, one in 
the northern region (Hospital de São João, Porto) and the other in the southern area of the 
country (Hospital de Santa Maria, Lisboa). The following type Candida strains; C. albicans ATCC 
18804, C. glabrata ATCC 2001, C. tropicalis ATCC 750, C. parapsilosis ATCC 22019, C. krusei 
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ATCC 6258, C. lusitaniae ATCC 34449, C. guilliermondii ATCC 6260 and C. dubliniensis ATCC 
MYA-646 were used in the present studies. The identification of yeast isolates was carried out by 
conventional biochemical techniques in both medical institutions using the VITEK (bioMérieux 
Vitek, Inc., MO, USA) or ID32C (bioMérieux Vitek) yeast identification systems. The isolates were 
stored on yeast extract peptone dextrose (YEPD) agar plates. In addition, Aspergillus fumigatus 
MUM 98.02, A. niger MUM 03.01, A. flavus MUM 00.29, A. terreus MUM 94.09, A. nidulans 
MUM 98.32, Cryptococcus neoformans var. neoformans ATCC 28957 and Saccharomyces 
cerevisiae Y10000, as well as Mycobacterium tuberculosis H37Rv, M. avium 3509, Escherichia 
coli HB101, Staphylococcus aureus 0400, Pseudomonas aeruginosa ATCC 27853 and Bacillus 
subtilis ATCC 6051 were used for PCR cross-reactivity testing. 
Furthermore, 27 BACTEC blood culture bottles (Becton Dickinson Microbiology Systems, 
MD, USA) which were identified as positive for bacteria and/or yeasts through the use of a blood 
culture instrument and Gram staining and 19 urine samples found to be positive for yeasts 
and/or bacteria were also directly analysed by PCR. Identification was simultaneously carried out 
using the VITEK yeast biochemical card. Twenty blood culture bottles and 14 urine samples were 
noted to contain yeasts, while negative controls included blood culture bottles and urine samples 
positive for different bacterial species. While no DNA isolation procedure was required for urine 
samples, Candida DNA was isolated from aliquots of blood culture bottles, in order to eliminate 
the presence of PCR inhibitory factors (see below). 
 
Primer design. Yeast-specific universal primers UNI1 (5’-GTCAAACTTGGTCATTTA-3’) 
and UNI2 (5’-TTCTTTTCCTCCGCTTATTGA-3’) were used to amplify the internal transcribed 
spacer regions 1 (ITS1) and 2 (ITS2), including the 5.8S rRNA of the most relevant yeast 
pathogens associated with human disease (Trost et al., 2004). In addition, the species-specific 
primers Calb, Cgla, Ckru, Cpar, Ctro, Clus, Cgui and Cdub were designed based on the sequence 
data for the ITS1 and ITS2 regions of the reference strains and of all clinical isolates from the 
Candida genus available in the EMBL/GenBank databases. The sequences were compared using 
the DNAMAN for Windows software (Lynnon Corporation, Quebec, Canada) in order to design 
primers to specifically amplify DNA from C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. 
tropicalis, C. lusitaniae, C. guilliermondii and C. dubliniensis, respectively (Table 1). In the 
multiplex PCR, the species-specific primers form a pair with universal primer UNI2, with the 
exception of Clus, which pairs with UNI1 (Figure 1). 
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Table 1. Universal and species-specific primers used in Candida species amplification and size of fragments 
visualized under agarose gel electrophoresis. 
 
Species Primer 
name 
Sequence (5’-3’) Amplicon size (bp)* 
Clinically relevant yeasts 
UNI1 
UNI2 
GTCAAACTTGGTCATTTA 
TTCTTTTCCTCCGCTTATTG 
(Trost et al., 2004) 
C. albicans Calb AGCTGCCGCCAGAGGTCTAA 583/446 
C. glabrata Cgla TTGTCTGAGCTCGGAGAGAG 929/839 
C. krusei Ckru CTGGCCGAGCGAACTAGACT 590/169 
C. tropicalis Ctro GATTTGCTTAATTGCCCCAC 583/507 
C. parapsilosis Cpar GTCAACCGATTATTTAATAG 570/370 
C. guilliermondii Cgui TTGGCCTAGAGATAGGTTGG 668/512 
C. lusitaniae Clus TTCGGAGCAACGCCTAACCG 433/329 
C. dubliniensis Cdub CTCAAACCCCTAGGGTTTGG 591/217 
 
* Amplicon sizes result from multiplex PCR amplification using yeast-specific primers (UNI1 and UNI2) and corresponding species-
specific primer. 
 
 
Figure 1. Multiplex PCR strategy. Organization of fungal ribosomal genes with universal and species-specific primer 
targets indicated. Arrows indicate the direction of PCR amplification. 
 
 
DNA isolation. For DNA extraction of yeasts in culture, cells were grown overnight in 
YEPD medium at 26ºC with aeration on a mechanical shaker (150 rpm) (Xu et al., 2000). Cells 
were harvested by centrifugation and the pellet suspended in 200 μl of lysis buffer (2% Triton X-
100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl, and 1 mM EDTA, pH 8.0). For cell disruption, 
200 μl of 0.5 mm-diameter glass beads and 200 μl of phenol/chloroform (1:1) were added and 
the tubes were shaken for three 60-second intervals interspersed with periods of cooling on ice. 
After disrupted cell debris was removed by a 5 min centrifugation at 3,000 g, the supernatant 
was collected and 1 ml of cold isopropanol was added before mixing by inversion. The tubes 
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were centrifuged for 3 min at 3,000 g and the sediment suspended in 400 μl of TE buffer (100 
mM Tris-HCl, 1 mM EDTA, pH 8.0). A 5 min treatment with RNase A (1 mg/ml) at 37ºC was 
then carried out before adding 10 μl of 3 M sodium acetate. DNA was further precipitated by 
addition of 1 ml of isopropanol, mixing by inversion and further centrifugation. Finally, the 
sediment was air-dried and the DNA suspended in 50 μl of ultra-filtered water. DNA content and 
purity were determined by spectrophotometry at 260 and 280 nm and diluted to a 100 ng/μl 
final concentration. The DNA isolation from whole blood and blood culture bottles was adapted 
from elsewhere (Flahaut et al., 1998) with minor alterations. Four hundred μl of 10× TXTE buffer 
(10 mM Tris-HCl, 1mM EDTA, 1% Triton X-100, pH 8.0) were added to 3.6 ml of blood sample 
and the mixture incubated for 20 min at room temperature to lyse blood cells. Yeast cells were 
collected by centrifugation at 3,000 g for 10 min and washed with 1× TXTE buffer and with 20 
mM Tris-HCl (pH 8.3). The erythrocyte-free pellet was then suspended in 180 μl of ATL lysis 
buffer and 20 μl of proteinase K (1.7 mg/ml). The mixture was incubated at 65ºC for 1 h, 200 μl 
of AL buffer were added and the sample was heated at 70ºC for 10 min. After these steps, 200 
μl of ethanol were added to each sample and the mixtures were applied to QIAamp mini spin 
columns with 2 ml collection tubes, centrifuged at 5,000 g for 1 min and washed twice with 500 
μl of AW buffer. The columns were then washed twice with 50 mM EDTA and twice with AW 
buffer in order to chelate PCR inhibitory factors. DNA was eluted with 100 μl of previously heated 
AL buffer and kept at -20ºC until PCR. ATL lysis buffer, AL buffer, AW buffer, proteinase K and 
the spin columns were purchased from Qiagen, Hilden, Germany. 
 
PCR amplification. Multiplex PCR amplification was performed in a 20 μl volume 
consisting of 0.8× PCR buffer [160 mM (NH4)2SO4, 670 mM Tris-HCl (pH 8.8)], 3.5 mM MgCl2, 
dNTP mixture (200 μM each), primer mixture (UNI1 and UNI2, 0.55 μM each; Cgui, 0.05 μM; 
Calb and Ckru, 0.15 μM each; Cgla, Ctro and Clus, 0.2 μM each; Cpar, 0.3 μM; Cdub, 0.4 μM), 
1 U Taq DNA polymerase and 50 ng genomic DNA template, with the remaining volume 
consisting of sterilized water. The amount of template DNA used was quantified by 
spectrophotometry. A 2 μl volume was used when the template was urine or isolated Candida 
DNA, either from whole blood samples or aliquots from blood culture bottles. For colony-PCR, 
part of a single colony was suspended directly in the PCR mixture with a sterile toothpick. PCR 
was routinely carried out in a Biometra Tpersonal (Whatman Biometra, Goettingen, Germany) 
thermal cycler under the following cycling conditions: 40 cycles of 15 s at 94ºC, 30 s at 55ºC, 
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and 45 s at 65ºC, after a 10 min initial period of DNA denaturation and enzyme activation at 
94ºC. Additionally, multiplex PCR reactions were performed in four different thermal cyclers: 
iCycler and MyCycler (Bio-Rad, CA, USA), Primus 96 (MWG Biotech AG, Ebersberg, Germany) 
and GeneAmp PCR System 9600 (Perkin-Elmer, MA, USA) in order to confirm PCR reaction 
reproducibility. Negative control reactions were performed simultaneously with each test run by 
replacing the template DNA with sterilized water in the PCR mixture. Ten μl aliquots of each 
amplification product were separated by electrophoresis in a 2% agarose gel. Ethidium bromide 
staining (0.5 μg/ml) allowed the visualization of DNA fragments with a digital imaging system 
(Alpha Innotech Corporation, CA, USA) and species identification was possible by comparison 
with a 100-bp DNA ladder (Fermentas International Inc., Ontario, Canada). Mycobacterium avium 
subsp. paratuberculosis strain k10, Mycobacterium tuberculosis CDC1551, and Nocardia 
farcinica IFM10152 were tested using in silico PCR (http://www.in-silico.com/multiplex_PCR/). 
 
Detection limit of Candida yeasts in whole blood. In order to determine the 
detection limit of Candida cells in whole blood by multiplex PCR, fresh human blood obtained 
from healthy volunteers was seeded with cells from each Candida species to a concentration of 
5×102 CFU/ml. Yeast-cell number was estimated by haemocytometer counting and confirmed by 
plating serial dilutions of seeded blood onto Sabouraud agar plates and colony counting after 2 
days of incubation at 30ºC. The seeded blood was then serially diluted with whole blood to obtain 
yeast concentrations ranging from 2.5×102 to 1.25 cells/ml and 3.6 ml of the diluted samples 
were used for isolation of Candida DNA. Multiplex PCR amplification was then carried out using 2 
μl of isolated DNA as template (see above). 
 
Flow cytometry analysis. In order to eliminate the interference of DNA from dead 
cells, cell viability was determined for quantification of DNA in samples. Plasma membrane 
integrity was determined by examining cellular permeability to propidium iodide (Sigma-Aldrich 
Corporation, MO, USA) as described elsewhere (de la Fuente et al., 1992). Fluorescence analysis 
was carried out by flow cytometry with an EPICS XL-MCL (Beckman-Coulter Inc., CA, USA) flow 
cytometer, equipped with an argon-ion laser emitting a 488 nm beam at 15 mW. 
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RESULTS 
 
Sequence analysis and multiplex PCR strategy. Previously designed fungus-
specific universal primers UNI1 and UNI2 were used to amplify the internal transcribed spacer 
regions 1 (ITS1) and 2 (ITS2), including the 5.8S rRNA region (Trost et al., 2004). As shown in 
Figure 1 and reported by Trost and colleagues, predicted PCR products obtained by amplification 
using these universal primers were found to vary among Candida species, ranging in length from 
433 bp (C. lusitaniae) to 929 bp (C. glabrata) (Trost et al., 2004). In addition, DNA from clinically 
relevant yeasts other than Candida, including species from the genus Cryptococcus, 
Saccharomyces and Trichosporon would also be amplified into a single PCR fragment using the 
universal primers (Trost et al., 2004). For most Candida species, the sizes of the obtained 
fragments are not sufficient to promote direct identification. Thus, species-specific variations 
within ITS1 and ITS2 sequences were used to design primers for amplification of an internal 
fragment with a lower length (Figure 1), that could allow direct identification by only a PCR 
reaction avoiding the restriction analysis described by Trost and collaborators (Trost et al., 2004). 
ITS1 and ITS2 sequences from the reference strains and from all clinical Candida isolates 
displayed in EMBL/GenBank database were analyzed by intraspecies alignments using DNAMAN 
for Windows software (Lynnon Corporation, Quebec, Canada) to find blocks of conserved regions 
among the different strains. These sequences were compared inter-species in order to find 
variable regions that allowed the design of specific primers to each species. Interferences from 
both C. orthopsilosis and C. metapsilosis in C. parapsilosis identification and C. famata and other 
species of the C. guilliermondii clade (C. fermentati and C. carpophila) in C. guilliermondii 
identification (Tavanti et al., 2005; Vaughan-Martini et al., 2005) were ruled out by sequence 
analysis and multiplex PCR. This in silico study was concluded with the design of primers in 
variable regions among species but at the same time conserved between strains (Table 1), thus 
excluding possible intraspecies variability. 
 
Multiplex PCR amplification. In order to develop a protocol that could allow the 
specific identification of each Candida species studied in a single reaction, a simple step-by-step 
protocol of multiplex PCR optimization was developed (Henegariu et al., 1997). The results of 
multiplex PCR using isolated DNA from each species allowed the identification of up to eight 
clinically relevant yeasts in a single PCR reaction by the use of eight species-specific primers 
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together with the previously described universal primers (Trost et al., 2004) (Figure 2A). Multiplex 
PCR directly from living/intact yeast whole cells (commonly referred as colony-PCR (Ward, 
1992)) was also assessed. PCR conditions were maintained and the DNA was replaced by whole 
yeast cells, where the initial 10 min at 94ºC in the PCR protocol was sufficient to disrupt cell 
integrity allowing DNA release. Multiplex PCR reactions performed with yeast cells yielded both 
universal and species-specific amplicons (Figure 2B). 
 
Identification of clinical yeast isolates. To validate the methodology described, a 
wide scan of 231 clinical isolates, previously characterized by conventional phenotypic systems, 
was carried out using the multiplex PCR-based approach. Comparison of the results of the two 
identification approaches (Table 2) showed discrepancies in species identification for 18 isolates 
representing 7.8% of the total. The multiplex PCR identification of the discrepant isolates was 
further confirmed using PCR fingerprinting (Figure 2E) (Correia et al., 2004), which demonstrated 
the accuracy of the multiplex PCR identifications. No isolates of C. dubliniensis were found in the 
clinical specimens provided by the healthcare institutions. For this reason, results for C. 
dubliniensis are not included in the agarose gel presented in Figure 2B. The most frequent 
misidentifications of the VITEK/ID32C analysis were of C. parapsilosis (7/18 of all discrepant 
identifications), followed by C. albicans (5/18), C. tropicalis (4/18), C. krusei (1/18) and C. 
guilliermondii (1/18). In addition, the most common misidentification was C. tropicalis for C. 
parapsilosis. Taking into account the misidentification percentage for each species regarding the 
number of isolates wrongly identified by the VITEK or ID32C systems, C. tropicalis was the most 
often misidentified species (16% of the C. tropicalis isolates), followed by C. parapsilosis (11.5%), 
C. guilliermondii (7.7%), C. albicans (5.6%) and C. krusei (5.3%). 
 
Identification of Candida species in polymicrobial mixtures. Theoretically, the 
strategy here described would be able to simultaneously identify in a single multiplex PCR 
reaction coexisting yeast species in mixed samples. In order to experimentally assess this 
hypothesis, samples with two or three mixed Candida species were tested. The results showed 
that the multiplex method discriminates the different species present in polyfungal samples 
(Figure 2C) by the amplification of the fragments corresponding to each Candida species present. 
In fact, multiple species can be identified to a maximum cell ratio of 1:10, where for lower ratios 
the less abundant yeast species could not be detected (data not shown).  
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Table 2. Comparative results between identification in hospital centres (based on VITEK or ID32C) and identification by multiplex PCR of clinical isolates of 
Candida species. Multiplex PCR amplification of the analysed yeast species bypass the errors associated with VITEK/ID32C identification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* PCR fingerprinting (Correia et al., 2004) confirmed the results obtained by multiplex PCR. 
 
 
VITEK/ID32C 
identification 
 Multiplex PCR identification*  
VITEK/ID32C 
misidentifications 
Species Isolates  C. 
albicans 
C. 
parapsilosis 
C. 
tropicalis 
C. 
krusei 
C. 
glabrata 
C. 
guilliermondii 
C. 
lusitaniae 
 (%) 
C. albicans 
C. parapsilosis 
C. tropicalis 
C. krusei 
C. glabrata 
C. guilliermondii 
C. lusitaniae 
90 
61 
25 
19 
18 
13 
5 
 
85 
0 
0 
0 
0 
0 
0 
3 
54 
2 
1 
0 
1 
0 
0 
4 
21 
0 
0 
0 
0 
0 
0 
0 
18 
0 
0 
0 
1 
0 
2 
0 
18 
0 
0 
0 
1 
0 
0 
0 
12 
0 
1 
2 
0 
0 
0 
0 
5 
 
5.6 (5/90) 
11.5 (7/61) 
16.0  (4/25) 
5.3 (1/19) 
0 (0/18) 
7.7 (1/13) 
0 (0/5) 
Total 231  85 61 25 18 21 13 8  7.8 
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In addition, in the case of polymicrobial samples (mixed fungal and bacterial cells), no 
detectable PCR products were obtained using as template Escherichia coli, Staphylococcus 
aureus, Pseudomonas aeruginosa and Bacillus subtilis bacterial DNA, although Candida species 
could be identified without interference (data not shown). This confirms the specificity of the 
proposed methodology. In addition, common microorganisms which usually cause infection in 
immunocompromised populations with candidaemia, such as Mycobacterium tuberculosis, M. 
avium and Nocardia farcinica did not present cross-reactivity with Candida species (data not 
shown). 
 
Identification of yeasts directly from urine and blood culture bottles. In order 
to directly apply this methodology to clinical samples, direct detection and identification of yeast 
cells in blood culture bottles (n=27) and urine samples (n=19) was assessed. To avoid cellular 
growth, the PCR reactions were performed in the samples from blood culture bottles immediately 
after detection of growth and in the case of urine samples, frozen aliquots were tested after 
positive indicators of development were obtained. The results for the Candida species present in 
the analyzed samples were in accordance to the presumptive identification provided by the 
healthcare institutions that carried out simultaneous phenotypic identification (Table 3). No cross-
reactivity was detected in control samples positive for bacteria (7 samples) and at the same time, 
no interference in the identification of Candida species was observed in polymicrobial samples (2 
samples constituted by C. albicans with either S. aureus or P. aeruginosa). 
A step forward in the application of the multiplex PCR described would be the detection 
of cases of candidaemia directly from blood samples.  In this sense, and to further characterize 
the sensibility of the methodology, the limit of detection in seeded whole blood was determined. 
Thus, cells of different Candida species were artificially inoculated in whole blood from healthy 
volunteers in concentrations ranging from 2.5×102 to 1.25 cells/ml and DNA was isolated from a 
3.6 ml sample. Cells in the exponential phase of growth were used and their viability (assessed 
as plasma membrane integrity) was confirmed by flow cytometry in order to exclude the presence 
of dead Candida cells that could contribute to the release of DNA, masking the sensitivity of the 
method (data not shown). Using the proposed multiplex protocol, the PCR products presented 
the characteristic mobility pattern, correctly identifying the species seeded in whole blood (Figure 
2D exemplifies the case of C. albicans). Additionally, the sensitivity of the multiplex PCR was 
found to be 2.15±0.25 cells per ml of blood. On other hand, in the particular case of simulated 
  38
polyfungal infections, both species could be correctly identified to a minimum limit of 
approximately 20 cells/ml, although one of them was always detected to the minimum limit 
achieved for individual species (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Agarose gel showing the results obtained for multiplex PCR of isolated yeast genomic DNA (A) or yeast 
whole cells (B) as template. Lanes: L – 100-bp DNA ladder; 1 - C. albicans, 2 - C. glabrata, 3 - C. krusei, 4 - C. 
tropicalis, 5 - C. parapsilosis, 6 - C. guilliermondii, 7 - C. lusitaniae and 8 - C. dubliniensis. (C) Multiplex PCR of 
Candida mixtures in 1:1 ratios. Lanes: L – 100-bp DNA ladder; M1 - C. albicans + C. glabrata, M2 - C. albicans + C. 
krusei, M3 - C. albicans + C. tropicalis, M4 - C. albicans + C. parapsilosis and M5 - C. albicans + C. glabrata + C. 
krusei. (D) Sensitivity of multiplex PCR. DNA was isolated from whole blood with different levels of artificial infection 
with C. albicans. Lanes: L – 100-bp DNA ladder; B1 – 2.5×102, B2 - 2.5×101, B3 - 5, B4 - 2.5 and B5 - 1.25 
cells/ml. (E) PCR fingerprinting using primer T3B of the Candida isolates with different identification using multiplex 
PCR and VITEK/ID32C. Lanes: L – 100-bp DNA ladder; 1 – C. albicans type strain; 2-6 – C. albicans (as identified 
by multiplex PCR); 7 – C. parapsilosis type strain; 8-14 – C. parapsilosis (as identified by multiplex PCR); 15 - C. 
tropicalis type strain; 16-19 – C. tropicalis (as identified by multiplex PCR); 20 – C. krusei type strain; 21 – C. krusei 
(as identified by multiplex PCR); 22 – C. guilliermondii type strain; 23 – C. guilliermondii (as identified by multiplex 
PCR). 
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Table 3. Comparative results between VITEK and multiplex PCR identification of Candida species present in blood culture bottles and urine samples. 
 
 
 
 
 
 
 
 
 
* Yeast-negative identification was proven by both VITEK and multiplex PCR 
 
 
 
 
 
 
C. albicans 
 
 C. glabrata  C. parapsilosis  C. tropicalis  Clinical  
Samples 
T
o
t
a
l
 
 VITEK Multiplex 
PCR 
 VITEK 
Multiplex 
PCR 
 VITEK 
Multiplex 
PCR 
 VITEK 
Multiplex 
PCR 
 
Yeast-negative 
Identification* 
Blood culture 
bottles 
27  13 13  4 4  2 2  1 1  7 
Urine 19  12 12  2 2  0 0  0 0  5 
Total 46  25 25  6 6  2 2  1 1  12 
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DISCUSSION 
 
The development of a simple approach to the identification of Candida species based on 
the combined use of universal yeast primers and Candida species-specific primers was 
undertaken. The universal primers were first reported by Trost and colleagues, who further 
developed a method based on the enzyme restriction of PCR fragments in order to identify a set 
of fungal pathogens (Trost et al., 2004). While universal primers provide a broad detection 
capability for yeast pathogens (Trost et al., 2004), in the present work, the presence of species-
specific primers allow differentiation of Candida at the species level in a single PCR reaction. The 
multiplex PCR strategy herein described takes advantage of the high-copy number of rRNA genes, 
the differences in the length of ITS regions and the high variability of these regions among 
Candida species. This strategy renders the method with a test matrix able to identify eight of the 
most clinically relevant yeast species, including the newly emerging C. dubliniensis, as shown 
with the type strain (Figure 2A). Together, both the universal and species-specific fragments 
result in characteristic band patterns, enabling easy identification of the Candida species in 
question. Similarly to other genotypic-based techniques, this method allows the identification of 
species that have non-standard morphologic, cultural and biochemical characteristics. 
Additionally to the amplification of isolated DNA, the identification of living/intact whole cells in 
the PCR mixture was also found to be possible (Figure 2B), thus bypassing the time-consuming 
DNA isolation steps and reducing the time required for identification. Another advantage of this 
methodology resides in the rapid identification in the same multiplex PCR reaction of the 
aetiological agents involved in polyfungal infections (Figure 2C). Such cases involving more than 
one yeast have been reported to occur with a frequency of approximately 5% among all 
candidaemias (Pulimood et al., 2002). Furthermore, identification of the yeast species was not 
hampered by the presence of bacteria frequently co-infecting candidaemia patients. 
The identification of Candida species was also carried out directly from clinical samples 
such as blood culture bottles and urine samples. The isolation of Candida DNA from aliquots of 
blood culture bottles required 2 h to lyse blood cells and recover DNA, 2 h for multiplex PCR 
amplification of isolated DNA and 1 h to perform agarose gel electrophoresis, including the time 
required to prepare the PCR mixture and agarose gel. Therefore, species can be identified within 
as little as 5 h, in contrast to phenotypic methods which can take several days (Reimer et al., 
1997). Furthermore, this methodology is highly sensitive since the number of yeast cells 
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detectable in artificially inoculated whole blood reached a minimum limit of 2.15±0.25 cells/ml 
(Figure 2D). This capacity may enable the method to detect low candidaemias occurring in the 
early stages of infection, given that there are often less than 10 Candida cells circulating per ml 
of blood in these situations (Isenberg, 1992). Moreover, this multiplex strategy is adaptable to 
diverse standard equipment currently in use in most clinical laboratories and if not, likely to be 
easily implemented. The technique is cost-effective since it only requires essentially PCR 
components and DNA isolation reagents. Furthermore, no DNA probes or expensive restriction 
enzymes are needed. Finally, the possibility of detection of candidaemia cases directly from 
patients’ whole blood is currently under investigation and efforts are being carried out to validate 
the applicability of the method in clinical settings. 
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                                                                                                CHAPTER 3 
 
Study of disease-relevant polymorphisms in the TLR4 and TLR9 genes: a 
novel method applied to the analysis of the Portuguese population 
 
 
Based on data from: 
 
Carvalho, A., Marques, A., Maciel, P. and Rodrigues, F. 
“Study of disease-relevant polymorphisms in the TLR4 and TLR9 genes: a novel method applied 
to the analysis of the Portuguese population” 
Mol Cell Probes. (2007) 21:316-20 
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ABSTRACT 
 
Toll-like receptors (TLRs) are cellular receptors that mediate recognition of microbial 
challenges and the subsequent inflammatory response. Genetic variations within these 
inflammation-associated genes may alter host-pathogen defence mechanisms affecting 
susceptibility towards infectious diseases. Taking into account the significance of these genes, we 
developed a simple and rapid method based in the bi-directional PCR amplification of specific 
alleles (Bi-PASA) for genotyping known sequence variants in TLR4 (Asp299Gly and Thr399Ile) 
and TLR9 (T-1237C) genes. This method allows genotype determination in a single reaction and 
is amenable to large scale analysis. We used Bi-PASA to characterize the distribution of these 
polymorphisms in the Portuguese population. A total of 388 randomly selected blood donors of 
Portuguese origin (203 females and 185 males) were genotyped and allele frequencies were 
determined. Among the tested individuals, 11.1% and 10.8% were heterozygous for Asp299Gly 
and Thr399Ile, respectively. In what concerns the T-1237C variation in TLR9, the variant allele 
was present in 19.4% of the individuals tested. Besides confirming the usefulness of the Bi-PASA 
in polymorphism analysis, the data presented provide valuable information on TLR 
polymorphisms in the Portuguese population that can be used to stratify risk patients with 
increased susceptibility to infection. 
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INTRODUCTION 
 
The innate immune system is able to recognize conserved motifs in pathogens in which 
pattern recognition receptors, including Toll-like receptors (TLRs), play an important role 
(Medzhitov and Janeway, 2000a). TLRs are a family of genetically conserved proteins identified 
as key components of the innate immune system, mediating recognition of microbial challenges 
and the subsequent inflammatory response (Medzhitov and Janeway, 2000b). The first of the 
currently known TLRs was described in 1997 as a human homologue of the Drosophila Toll 
protein, later designated TLR4 (Medzhitov et al., 1997). The complete TLR family allows the host 
to detect infection by most, if not all, types of microbial pathogens. Well characterized receptor-
ligand pairs include TLR4 and lipopolysaccharide (LPS) (Hoshino et al., 1999; Poltorak et al., 
1998), TLR5 and bacterial flagellin (Hayashi et al., 2001), TLR3 and viral double-stranded DNA 
(Alexopoulou et al., 2001), TLR9 and bacterial hypomethylated DNA (Hemmi et al., 2000) and 
TLR2, in association with TLR1 or TLR6, and a variety of cell wall components from Gram-positive 
bacteria (Kirschning and Schumann, 2002). 
Cellular activation via TLRs triggers not only innate immune responses but also initiates 
adaptive immunity (Akira et al., 2001). Due to the significance of TLRs in the immune system, 
genetic variations within these genes could have a major impact upon host immune response to 
pathogens and thus, an increased susceptibility to infection. Regarding TLRs, several 
polymorphisms are already largely studied and characterized concerning the phenotypical 
outcome, such as polymorphisms in TLR4 [A+896G (SNP ID: rs4986790) and C+1196T (SNP 
ID: rs4986791)]. These polymorphisms are located in the coding sequence resulting in amino 
acid exchanges: an aspartic acid for a glycine at position 299 (Asp299Gly) and a threonine for an 
isoleucine at position 399 (Thr399Ile), respectively, affecting the extracellular domain of this 
receptor. Others, such as those concerning TLR9, have just recently started to be characterized 
and their functional importance elucidated. Among these, the most studied is T-1237C (SNP ID: 
rs5743836), a polymorphism located within the putative promoter region known to influence 
transcriptional regulation of the TLR9 gene. 
Arbour and colleagues were the first to describe that the two mutations affecting the 
extracellular domain of TLR4 protein at the 299 and 399 residues were associated with blunted 
physiological responses to inhaled LPS (Arbour et al., 2000). A large number of association 
studies followed and the most relevant are summarized in Table 1. 
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Table 1. Summary of association studies between TLR4/TLR9 polymorphisms and infectious and inflammation-related diseases. 
Reference Association study 
Patients 
(n) 
Controls 
(n) 
TLR SNP 
Case vs. control 
(%) 
p value 
(Arbour et al., 2000) Hyporesponsiveness to inhaled LPS 31 57 Asp299Gly 
Thr399Ile 
22.6 vs. 5.8 0.029 
(Lorenz et al., 2002b) Septic shock 91 73 Asp299Gly 5.5 vs. 0 0.05 
(Lorenz et al., 2002a) Premature birth associated to infection 440 351 Asp299Gly 
Thr399Ile 
23.8 vs. 15.9 0.028 
(Agnese et al., 2002) Gram-negative infections 77 39 Asp299Gly 
Thr399Ile 
18.0 vs. 12.8 0.004 
(Tal et al., 2004) Respiratory syncytial virus infection 99 82 Asp299Gly 
Thr399Ile 
20.2 vs. 4.9 0.003 
(Edfeldt et al., 2004) Myocardial infarction associated to infection 1213 1561 Asp299Gly 
Thr399Ile 
10.7 vs. 7.9 0.004 
(Hawn et al., 2005) Legionnaire’s disease 108 510 Asp299Gly 
Thr399Ile 
2.5 vs. 6.5 0.025 
(Rezazadeh et al., 2006) Brucellosis 198 111 Asp299Gly 33.6 vs. 20.7 <0.0001 
(Mockenhaupt et al., 2006) Severe malaria 70 51 
TLR4 
Thr399Ile 24.1 vs. 17.6 <0.05 
(Lazarus et al., 2003) Asthma 67 152 T-1237C 23.4 vs. 14.5 0.042 
(Torok et al., 2004) Crohn’s disease 174 265 
TLR9 
T-1237C 19.3 vs. 11.9 0.0036 
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Since their identification, the Asp299Gly and Thr399Ile mutations have been studied for 
their association with various infectious and inflammatory diseases. Specifically, a positive 
association of the Asp299Gly mutation with increased susceptibility to Gram-negative 
bacteraemia and septic shock was found (Agnese et al., 2002; Lorenz et al., 2002b). 
Interestingly however, no association between the Asp299Gly and/or Thr399Ile mutations was 
found for other diseases of infectious aetiology, including candidiasis (Morre et al., 2002), 
tuberculosis (Newport et al., 2004) or meningococcal disease (Read et al., 2001). The variation 
T-1237C in the promoter region of TLR9, on the other hand, has been shown to be associated 
with an increased risk for asthma (Lazarus et al., 2003) and preliminary data regarding a 
possible positive association with Crohn’s disease was also reported (Torok et al., 2004). 
Nevertheless, some studies also reported no association between this polymorphism and 
susceptibility to systemic lupus erythematosus (De Jager et al., 2006) and atopy (Berghofer et 
al., 2005). 
Thus, assessment of polymorphisms in TLRs may have a potential clinically usefulness 
for risk stratification of patients possibly more vulnerable to infections. Some of the previously 
developed methods are, to a certain extent, attractive laboratory-tailored approaches for 
genotyping polymorphisms in TLR genes, such as the real-time PCR-based method developed by 
Hamann et al. (Hamann et al., 2004) or the single tube PCR reaction based on exonuclease 
degradation of allele-specific probes described by van Rijn et al. (van Rijn et al., 2004). However, 
most of the genotyping techniques currently available are still either time-consuming and 
laborious or require expensive equipment (Heesen et al., 2003; Lorenz et al., 2001a; Schmitt et 
al., 2002; van Rijn et al., 2004). In this sense, we adapted a simple and rapid method, allowing 
genotype determination in a single reaction based in the bi-directional PCR amplification of 
specific alleles (Bi-PASA) (Liu et al., 1997) in both the TLR4 (Asp299Gly, Thr399Ile) and TLR9 (T-
1237C) genes, a methodology amenable to large scale analysis, using technology available in 
most scientific laboratories. 
 
 
MATERIALS AND METHODS 
 
Bi-PASA uses a combination of four primers, two outer primers (named P and Q) and two 
inner allele-specific primers (termed M and W). The inner primers are characterized by containing 
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a 10-nucleotide G+C-rich 5’ tail, which prevents “megapriming” and enhances the efficiency of 
amplification. Depending on the genotype, Bi-PASA produces two or three overlapping fragments. 
PQ is always produced and serves as a positive control. PW and MQ are present in a 
heterozygote individual, but PW is only produced in wild-type homozygote and MQ only in 
homozygous mutant samples (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Predicted band pattern obtained with Bi-PASA genotyping (A). Agarose gel electrophoresis showing results 
of Bi-PASA genotyping for Asp299Gly (B), Thr399Ile (C) and T-1237C (D). 
 
 
Primers for Bi-PASA were designed following the guidelines proposed by Liu and 
colleagues (Liu et al., 1997), taking into account both the melting temperature of both the 
primers and the largest PCR segment (PQ). The primers used in this study are shown in Table 2. 
The Bi-PASA methodology was optimized using DNA samples from individuals with known 
genotype for the polymorphisms being studied (Figure 1B-D). These samples were previously 
genotyped by Berghöfer et al. and Hamann et al. using real-time PCR-based methodologies and 
confirmed by direct sequencing (Berghofer et al., 2005; Hamann et al., 2004). 
DNA was isolated from whole blood samples using the salting-out procedure described by 
Miller and colleagues (Miller et al., 1988) and PCR amplification was performed in a 20 μl 
volume that included autoclaved ultra-filtered water, PCR buffer (1.6×), dNTP mixture (200 μM 
each), primers (0.05-0.4 μM each; for details see Table 2), Taq DNA polymerase (1 U/20 μl) and 
approximately 50 ng genomic DNA templates. PCR cycling conditions included 35 cycles of 15 s 
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at 94ºC, 30 s at 57ºC (or 48ºC for Asp299Gly), and 45 s at 65ºC, after a 10-min initial period of 
DNA denaturation and enzyme activation at 94ºC. The amplified fragments had sizes readily 
distinguishable by electrophoresis through a 2% agarose gel. The results obtained for the 
genotype of the Portuguese population by Bi-PASA were further validated by sequencing analysis 
of 10 randomly selected samples (data not shown). 
 
 
Table 2. Bi-PASA primers used in this study. 
 
Gene Polymorphism Primer 
Primer final 
concentration 
(μM) 
Asp299Gly 
P: 5’-AGAACTTAATGTGGCTCACAAT-3’ 
Q: 5’-GAAAAAGCATTCCCACCTTTG-3’ 
W: 5’- ggcggcggggTTAAATAAGTCAATAATAT-3’ 
M: 5’- gggccgggggTACTACCTCGATGG-3’ 
0.1 
0.1 
0.4 
0.4 
TLR4 
Thr399Ile 
P: 5’-CTGGCTGGTTTAGAAGTCCA-3’ 
Q: 5’-ATTGAAAGCAACTCTGGTGTG-3’ 
W: 5’-ggcggcggggAAATACTTTAGGCTG-3’ 
M: 5’-gggccgggggTGATTTTGGGACAAT-3’ 
0.1 
0.1 
0.1 
0.1 
TLR9 T-1237C 
P: 5’-TCATTCAGCCTTCACTCAGA-3’ 
Q: 5’-CACATTCAGCCCCTAGAGGG-3’ 
W: 5’-ggcggcggggGTGCTGTTCCCTCTGCCTGA-3’ 
M: 5’-gggccgggggATGAGACTTGGGGGAGTTTC-3’ 
0.4 
0.4 
0.05 
0.05 
 
 
RESULTS AND DISCUSSION 
 
After written informed consent was obtained from each volunteer, a total of 388 
randomly selected blood donors of Portuguese origin (203 females and 185 males) were 
genotyped using Bi-PASA. Among the tested individuals, 43/388 (11.1%) and 42/388 (10.8%) 
were heterozygous for Asp299Gly and Thr399Ile polymorphisms, respectively. None of the 
individuals showed a homozygous TLR4 polymorphism. In what concerns the T-1237C variation 
in TLR9, 67/388 (17.3%) were heterozygous and 8/388 (2.1%) were homozygous for this 
polymorphism. Based on the control samples of a large number of published studies (Vogel et 
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al., 2005), the two TLR4 polymorphisms, Asp299Gly and Thr399Ile, are known to be present at 
an overall allele frequency of 6.4±2.8 (range, 0-19.6; n=38 studies) and 7.2±3.8 (range, 0-13, 
n=11), respectively. However, reports of differences in the frequencies of these two 
polymorphisms among different ethnic groups have been published (Newport et al., 2004; 
Smirnova et al., 2001). In fact, considering the data currently available on the Entrez SNP 
database (Table 3), the frequency of TLR4 Asp299Gly polymorphism is much higher in African 
Americans than in Europeans and sub-Saharan Africans, in contrast to Asians, where this 
particular polymorphism does not seem to occur. The overall frequencies of Thr399Ile are similar 
to that of Asp299Gly, although no data is available for African Americans. African Americans also 
display a higher frequency of the TLR9 polymorphism than Europeans and Asians. Comparing 
with our results, we can observe that TLR4 Asp299Gly and Thr399Ile allele frequencies in the 
Portuguese population are higher than those described for the European population 
characterized in the Entrez database, although similar to those of controls published in 
association studies using European populations. Concerning TLR9, the frequency of T-1237C in 
the Portuguese population is similar to the one presented in the database for the European 
population. 
 
Table 3. Allele frequencies of each TLR polymorphism in distinct ethnic populations [data from Entrez SNP 
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp) in November, 2006] and in our 
study in the Portuguese population. 
 
 Allele frequencies 
TLR SNP  
 This study  European  Asian   
African 
American 
 
Sub-Saharan 
African 
Asp299Gly 
A 
G 
 
0.889 
0.111 
 
0.967 
0.033 
 
1.000 
0 
 
0.848 
0.152 
 
0.967 
0.033 
Thr399Ile 
C 
T 
 
0.892 
0.108 
 
0.967 
0.033 
 
1.000 
0 
 n/a  
1.000 
0 
T-1237C 
C 
T 
 
0.806 
0.194 
 
0.841 
0.159 
 
0.974 
0.026 
 
0.750 
0.250 
 n/a 
 
n/a – not available 
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Distributions of both TLR4 and TLR9 genotypes did not deviate from those predicted by 
the Hardy-Weinberg equilibrium (Asp299Gly, p=0.388; Thr399Ile, p=0.410; T-1237C, p=0.58). 
In addition and as expected, both TLR4 polymorphisms are in total linkage disequilibrium 
(D’=1.000). In fact, co-segregation among these two mutations has also been largely stated 
(Hartel et al., 2004; Lorenz et al., 2002b; Tal et al., 2004). 
In conclusion, the data herein presented provides valuable information on TLR 
polymorphisms in the Portuguese population that can be used in future studies to stratify patients 
regarding susceptibility to infection. Our results clearly show that Bi-PASA is a valuable 
methodology for genotyping studies. In addition, this method can easily be applied in studies of 
large populations, and further applied for the study of other polymorphisms, as it is a cost-
effective technique, where in a single reaction the genotype of the individuals can be determined. 
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ABSTRACT 
 
Toll-like receptors (TLRs) are important components of innate immunity. While certain 
genetic variations have been associated with invasive aspergillosis, none are described for 
chronic pulmonary or allergic aspergillosis. We investigated the association between 
polymorphisms in the TLR2, TLR4, and TLR9 genes and susceptibility to non-invasive forms of 
pulmonary aspergillosis. A significant association was observed between allele G on Asp299Gly 
(TLR4) and chronic cavitary pulmonary aspergillosis (p=0.003; odds ratio [OR], 3.46). In 
addition, susceptibility to allergic bronchopulmonary aspergillosis was associated with allele C on 
T-1237C (TLR9) (p=0.043; OR, 2.49). No particular polymorphism was associated with severe 
asthma with fungal sensitization. These findings differ from those described in invasive 
aspergillosis, suggesting important innate immune differences in the pathogenesis of different 
forms of aspergillosis. 
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INTRODUCTION 
 
Aspergillus fumigatus is the most prevalent airborne, filamentous fungal pathogen in 
humans. It is the main cause of aspergillosis, an important condition that can be manifested as 
invasive, chronic non-invasive and allergic syndromes (Denning, 1998). Allergic 
bronchopulmonary aspergillosis (ABPA) is an allergic hypersensitivity to bronchial colonization by 
Aspergillus species, which affects mainly patients with asthma and patients with cystic fibrosis 
(Greenberger, 2003). A severe asthma phenotype associated with fungal sensitization (SAFS), 
distinguished from ABPA by lower IgE levels, can also develop. In contrast, chronic cavitary 
pulmonary aspergillosis (CCPA) is a subacute and slowly destructive infection form of pulmonary 
aspergillosis. 
Although the immunological status of the host is probably the main determinant of the 
clinical presentation of aspergillosis, very little is known about this subject. Protective defence 
against pathogenic fungi requires effective innate and adaptive (antigen-specific) immune 
responses. In recent years, considerable attention has focused on the importance of innate 
immunity, the first line of defence which differentiates self from non-self and activates the 
adaptive immune system through specific signals (Fearon and Locksley, 1996; Medzhitov and 
Janeway, 1997). Genetic studies revealing additional risk factors for aspergillosis are needed, 
mainly for patients with no obvious predisposing conditions such as neutropenia and receipt of 
corticosteroids. The latest evidence has focused on proteins that belong to the collectin family, 
including the lung surfactant protein (SP), mannose-binding lectin (MBL), and pentraxin 3 (PTX3). 
Allele variants in a gene encoding SP-A have been associated with increased susceptibility to both 
ABPA and CCPA (Saxena et al., 2003; Vaid et al., 2007). In addition, treatment with SP-A or SP-D 
was shown to be protective against pulmonary hypersensitivity induced by A. fumigatus, by 
lowering blood eosinophilia, pulmonary infiltration and specific antibody levels (Madan et al., 
2001). Also, distinct MBL genotypes have been linked with CCPA (Crosdale et al., 2001; Vaid et 
al., 2007), and an intronic polymorphism in the MBL gene was found to underlie elevated levels 
of MBL and greater disease severity in ABPA patients (Kaur et al., 2006). On the other hand, 
PTX3 was shown to play a non-redundant role in resistance to Aspergillus, with PTX3-null mice 
showing increased susceptibility to invasive pulmonary aspergillosis (Garlanda et al., 2002). In 
addition, immunocompromised mice with invasive aspergillosis have been successfully treated 
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with PTX3 (Gaziano et al., 2004). In conjunction, these exciting data revealed the importance of 
innate immunity in the host response against Aspergillus infections. 
The host innate immune system is able to recognize conserved motifs in fungal 
pathogens through pattern recognition receptors, including Toll-like receptors (TLRs) (Medzhitov 
and Janeway, 1998). TLRs are transmembrane proteins characterized by an extracellular domain 
containing leucine-rich repeats (LRR) and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain, 
which activates common signalling pathways. TLRs mediate the recognition of microbial 
challenges and the subsequent inflammatory response through rapid changes in the expression 
of genes encoding cytokines and inflammatory molecules (Akira et al., 2001). More specifically, 
TLR2 and TLR4 have been implicated as important components of the initial host immune 
response to fungal pathogens, both yeasts and moulds (Romani, 2004). 
Several variations in TLR genes have been studied, including that of Asp299Gly 
(A+896G) in the TLR4 gene (Schroder and Schumann, 2005). This results in an amino acid 
change in the LRR domain of TLR4, impairing its recognition ability. This single nucleotide 
polymorphism (SNP) has been correlated with diminished airway response to inhaled 
lipopolysaccharide in healthy individuals (Arbour et al., 2000). On the other hand, the Arg753Gln 
(G+2258A) polymorphism, which affects the TIR domain of TLR2, impairs signal transduction 
and its functional activity. Another SNP, T-1237C, located within the putative promoter region of 
the TLR9 gene has been implicated in chronic inflammatory diseases including asthma (Lazarus 
et al., 2003) and Crohn’s disease (Torok et al., 2004). Moreover, TLRs have also been 
associated with several pathological conditions affecting the lungs (Basu and Fenton, 2004). 
Thus, due to the significance of innate immunity in host defence, genetic variations in the genes 
of this system could have a major impact on immune responses to Aspergillus infections. 
In the present population-based, case-control study, we aimed to explore the contribution 
made by polymorphisms in the TLR2, TLR4 and TLR9 genes to susceptibility to different forms of 
aspergillosis, namely CCPA, ABPA, and SAFS. 
 
 
MATERIALS AND METHODS 
 
Study population. The study population comprised 76 patients; males and females 
were equally distributed. Mean age (±SD) was 57.6 (±11.8) years. The main diagnoses were 
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CCPA (n=40), ABPA (n=22), and SAFS (n=14). These individuals were recruited from a cohort of 
patients attending South Manchester University Hospitals NHS Trust (SMUHT, UK) for 
Aspergillus-related diseases. Eighty unrelated healthy individuals of identical ethnicity were 
included as controls. These controls gave no previous history of pulmonary disease. Informed 
written consent was obtained from all participants. 
 
Clinical evaluation. The clinical definitions were as follows (Denning et al., 2003). 
CCPA was diagnosed in the presence of the following symptoms and/or results: (1) chronic 
pulmonary or systemic symptoms with exclusion of other pulmonary pathogens, (2) radiological 
evidence of progressive pulmonary lesions with surrounding inflammation (with or without an 
intracavitary mass), (3) precipitating (IgG) antibody to Aspergillus in the serum, and (4) 
persistently elevated inflammatory markers (e.g., C-reactive protein, erythrocyte sedimentation 
rate, or plasma viscosity). 
 The diagnostic criteria for ABPA included the following symptoms and/or results (Tillie-
Leblond and Tonnel, 2005): (1) asthma, (2) total serum IgE concentration ≥1000 IU/ml, (3) 
elevated A. fumigatus-specific serum IgE levels, (4) precipitating antibodies to A. fumigatus in the 
serum (not always present in patients with long-standing ABPA), and (5) central bronchiectasis. 
The minor diagnostic criteria for ABPA were as follows: peripheral blood eosinophilia (often 
absent in patients on steroids), repeated detection of Aspergillus in sputum, expectoration of 
brown plugs or flecks, and history of recurrent pulmonary infiltrates (transient or fixed). 
 The diagnosis of SAFS was based on the basis of the following recently proposed criteria 
(Denning et al., 2006): (1) severe asthma, (2) total IgE <1,000 IU/ml and (3) positive skin prick 
test and/or raised specific IgE to A. fumigatus. We included in this study only SAFS who reacted 
to A. fumigatus. In contrast to patients with ABPA, patients with SAFS usually do not give a 
history of productive cough containing mucous plugs and infrequently have positive sputum 
cultures for fungi. 
 
 Genotyping of TLR2, TLR4 and TLR9 polymorphisms. Genotype determination of 
polymorphisms in TLR2 (Arg753Gln; SNP id: rs5743708), TLR4 (Asp299Gly; SNP id: 
rs4986790) and TLR9 (T-1237C; SNP id: rs5743836) genes was performed by use of bi-
directional PCR amplification of specific alleles (Bi-PASA), as described elsewhere (Carvalho et 
al., 2007). Details about the primers used in this study are shown in Table 1. 
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Table 1. PCR primers used to analyse polymorphisms in TLR2, TLR4 and TLR9 genes by use of Bi-PASA 
genotyping. 
 
NOTE. P, left outer primer; Q, right outer primer; W, inner wild-type primer; M, inner mutant primer 
 
 
Statistical analysis. The Fisher exact test and Pearson χ2 test were used to compare allele 
frequencies between patient groups and controls. Consistency of genotype frequencies with the 
Hardy–Weinberg equilibrium was tested using a χ2 test on a contingency table of observed vs. 
predicted genotype frequencies. χ2 values, odds ratios, and p values were calculated with 95% 
confidence intervals. 
 
 
RESULTS 
 
TLR polymorphisms in the control population were characterized as follows (Table 2). Of 
the 80 control patients studied, 5 of 80 (6.2%), 10 of 80 (12.5%), and 15 of 80 (18.8%) patients 
were heterozygous for Arg753Gln (G/A), Asp299Gly (A/G), and T-1237C (T/C) polymorphisms, 
respectively. In addition, no homozygous mutation was observed in controls (i.e., A/A for 
Target gene, 
SNP 
Primer sequence (5’→3’) 
Primer 
concentration, 
μM 
DNA 
fragment 
sizes, bp 
TLR2 
     Arg753Gln 
P: CTCCAGGCCAAAAGGAAGC 
Q: AAAGATCCCAACTAGACAAAGA 
W: ggcggcgggggccTGTTCATTATCTTCC 
M: gggccgggggTTCTGCAAGCTGCA 
0.1 
0.1 
0.1 
0.1 
PQ: 524 
PW: 399 
MQ: 152 
TLR4 
     Asp299Gly 
P: AGAACTTAATGTGGCTCACAAT 
Q: GAAAAAGCATTCCCACCTTTG 
W: ggcggcgggggccTTAAATAAGTCAATAATAT 
M: gggccgggggTACTACCTCGATGG 
0.1 
0.1 
0.4 
0.4 
PQ: 644 
PW: 455 
MQ: 220 
TLR9 
     T-1237C 
P: TCATTCAGCCTTCACTCAGA 
Q: CACATTCAGCCCCTAGAGGG 
W: ggcggcgggggccTGCTGTTCCCTCTGCCTGA 
M: gggccgggggATGAGACTTGGGGGAGTTTC 
0.4 
0.4 
0.05 
0.05 
PQ: 644 
PW: 395 
MQ: 275 
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Arg753Gln, G/G for Asp299Gly, or C/C for T-1237C). The distribution of genotypes did not 
deviate from those predicted by the Hardy-Weinberg equilibrium. 
There was no significant difference in patients with ABPA and control patients with 
respect to allele frequencies or genotype distribution of the TLR2 and TLR4 polymorphisms 
(Table 2). The G/A genotype in TLR2 was not detected in any patient with ABPA. Although 
patients with ABPA had a lower frequency of the G allele in TLR4, compared with control patients 
(2.3% vs. 6.3%), this difference did not reach statistical significance (p=0.463). Patients with 
ABPA had a significantly higher frequency of allele C for the T-1237C SNP in TLR9 than control 
patients (20.5% vs. 9.4%; p=0.043; odds ratio [OR], 2.49). 
The frequency of allele A for the TLR2 polymorphism among patients with SAFS was 
more than twice that observed among control patients (7.1% vs. 3.1%), although this difference 
was not statistically significant (p=0.280). No difference was observed regarding the TLR4 
variation between patients with SAFS and control patients; both presented similar allele 
frequencies. Patients with SAFS had a lower frequency of allele C in the TLR9 gene, although this 
difference was nonsignificant in comparison with control patients (3.6% vs. 9.4%; p=0.474). 
When patients with SAFS and ABPA were considered together and compared to control patients, 
no difference in allele frequency in the TLR genes was observed (data not shown). 
Patients with CCPA demonstrated a statistically significant higher frequency of allele G in 
the TLR4 gene, compared with controls (18.8% vs. 6.3%; p=0.003; OR, 3.46). The frequency of 
SNPs in the TLR2 and TLR9 genes was similar for patients with CCPA and control patients. 
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Table 2. Distribution of genotypes and allele frequencies of the studied polymorphisms in TLR2, TLR4, TLR9 genes in study and control patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE. ABPA, allergic bronchopulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; CI, confidence interval; OR, odds ratio, SAFS, severe asthma with fungal 
sensitization. χ2 and P values were calculated regarding allele frequencies. 
Gene, SNP 
Study group 
(n) 
Genotype 
n (% frequency) 
Allele 
n (% frequency) 
χ2 p OR (95% CI) 
 G/G G/A A/A G A 
Controls (80) 75 (93.8) 5 (6.2) 0 (0.0) 155 (96.9) 5 (3.1) 
 
ABPA (22) 22 (100) 0 (0.0) 0 (0.0) 44 (100.0) 0 (0.0) 1.41 0.587 1.032 (1.004-1.061) 
SAFS (14) 12 (85.7) 2 (14.3) 0 (0.0) 26 (92.9) 2 (7.1) 1.07 0.280 2.385 (0.439-12.944) 
TLR2 
Arg753Gln 
CCPA (40) 38 (95.0) 2 (5.0) 0 (0.0) 78 (97.5) 2 (2.5) 0.07 1.000 0.795 (0.151-4.190) 
 A/A A/G G/G A G 
Controls (80) 70 (87.5) 10 (12.5) 0 (0.0) 150 (93.8) 10 (6.3) 
 
ABPA (22) 21 (95.5) 1 (4.5) 0 (0.0) 43 (97.7) 1 (2.3) 1.07 0.463 0.349 (0.043-2.802) 
SAFS (14) 12 (85.7) 2 (14.3) 0 (0.0) 26 (92.9) 2 (7.1) 0.03 0.695 1.154 (0.239-5.570) 
TLR4 
Asp299Gly 
CCPA (40) 25 (62.5) 15 (37.5) 0 (0.0) 65 (81.3) 15 (18.8) 8.93 0.003 3.462 (1.477-8.110) 
 T/T T/C C/C T C 
Controls (80) 65 (81.2) 15 (18.8) 0 (0.0) 145 (90.6) 15 (9.4) 
 
ABPA (22) 14 (63.6) 7 (31.8) 1 (4.54) 35 (79.5) 9 (20.5) 4.08 0.043 2.486 (1.005-6.145) 
SAFS (14) 13 (92.9) 1 (7.1) 0 (0.0) 27 (96.4) 1 (3.6) 0.03 0.474 0.358 (0.045-2.825) 
TLR9 
T-1237C 
CCPA (40) 33 (82.5) 7 (17.5) 0 (0.0) 73 (91.3) 7 (8.8) 0.02 0.874 0.927 (0.362-2.373) 
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DISCUSSION 
 
TLR4 is among the major receptors involved in the recognition of pathogenic fungi and 
the initiation of the inflammatory response (Bellocchio et al., 2004b; Braedel et al., 2004; Tillie-
Leblond and Tonnel, 2005; Wang et al., 2001b). Wang et al. proposed TLR4 as the main 
receptor for Aspergillus hyphae, because monoclonal antibodies directed against CD14 and TLR4 
partially inhibited TNF-α release from human monocytes stimulated by A. fumigatus hyphae 
(Wang et al., 2001b). Accordingly, TLR4-deficient mice have shown increased susceptibility to A. 
fumigatus infection (Netea et al., 2003). Netea et al. showed that macrophages from TLR4-
deficient mice produced less TNF-α and IL-1 than did macrophages from control mice upon 
stimulation with A. fumigatus conidia but not with hyphae (Netea et al., 2003). These data 
suggest that TLR4-mediated signals might be lost during Aspergillus germination, therefore 
implying that this phenotypic switching might be a mechanism to escape the immune system. 
Interestingly, we found the Asp299Gly polymorphism (TLR4) to be highly associated with CCPA 
(p<0.01; OR, 3.46). This SNP has not been previously observed to be associated with acute 
invasive aspergillosis (Kesh et al., 2005). Because its presence does not ultimately affect signal 
transduction and cytokine production in mononuclear cells challenged with A. fumigatus (van der 
Graaf et al., 2005), a putative mechanism for disease association would be an abnormal TLR4 
extracellular domain, which hampered its function by disrupting microbial recognition. Patients 
with CCPA appear to have multiple defective immune responses, of which this may be one in a 
minority of patients. On the other hand, allele G on Asp299Gly was slightly less frequent in ABPA 
patients. This is perhaps unexpected, as it has been shown to be protective in hyper-
inflammatory states, such as atherosclerosis, by diminishing the levels of proinflammatory 
cytokines (Kiechl et al., 2002). The significance, if any, of this observation requires a study 
involving a larger number of patients with ABPA for clarification. 
We observed no association between TLR2 polymorphisms and susceptibility to CCPA. 
Similar findings were previously described for patients with invasive aspergillosis (Kesh et al., 
2005). Interestingly, the TLR2 SNP was not present in any patient with ABPA, which could argue 
for a protective role against ABPA. It is curious in this regard that TLR2-deficient mice are highly 
susceptible to experimental ABPA (L. Romani, unpublished observations). Ultimately, the 
numbers in our study population were too small to show any significant difference, suggesting at 
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maximum a weak effect. For the same reason, one can speculate that allele A might increase the 
risk for SAFS. 
Also interesting was the association of ABPA with the TLR9 SNP (p<0.05; OR, 2.49). 
TLR9 is a receptor that detects unmethylated CpG motifs prevalent in bacterial and viral DNA 
(Hemmi et al., 2000). As A. nidulans has been shown to be virtually devoid of genomic cytosine 
methylation (Antequera et al., 1984) (which is probably also true for A. fumigatus), TLR9 
activation by CpG motifs may occur after lysis of fungal cells during Aspergillus infections. 
However, the importance of TLR9 in aspergillosis is still obscure. Although both conidia and 
hyphae of A. fumigatus seem to signal through TLR9 on murine neutrophils (Bellocchio et al., 
2004b), TLR9-deficient mice showed paradoxically greater conidiocidal activity and hyphal 
damage than wild-type mice. In addition, TLR9 has been associated with anti-allergic activities 
(Racila and Kline, 2005). Accordingly, the TLR9 SNP has been associated with an increased risk 
of asthma (Lazarus et al., 2003), and TLR9 agonists are under development for patients with 
asthma and other allergic conditions. It remains to be elucidated if this constitutes an 
independent risk factor for ABPA, since all ABPA patients in our cohort were also diagnosed with 
asthma. In addition, work by Novak et al. (Novak et al., 2007) showed that the C allele of T-
1237C decreases TLR9 expression, which could also be proposed as a feature underlying 
susceptibility to ABPA. 
Due to the limited number of patients in the study, the importance of the TLR2 SNP in 
patients with aspergillosis cannot be underestimated, although its association with CCPA seems 
statistically improbable. No polymorphism was associated with the SAFS phenotype, reflecting 
either the limited number of patients, or more likely different pathogenesis. Also, the importance 
of polymorphisms affecting other TLR genes (as well as other SNPs in the TLRs investigated here) 
cannot be excluded. Because multiple receptors appear to be involved in the recognition of 
different components of Aspergillus, a better understanding of the signalling processes involved 
in innate immunity is ultimately required. 
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Polymorphisms in Toll-like receptor genes and susceptibility to 
infections in allogeneic stem cell transplantation 
 
 
Based on data from: 
 
Carvalho, A., Carotti, A., Aloisi, T., Guarrera, O., Bistoni, F., Aversa, F., Romani, L., Rodrigues, F. 
and Pitzurra, L. 
Original manuscript under preparation for submission in an international peer-reviewed journal 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  67 
ABSTRACT 
 
 The discovery of genetic variations in the genes encoding for Toll-like receptors (TLRs) 
has highlighted a potential link between genomic variation of the host and susceptibility to 
infections. We investigated the association between polymorphisms in the TLR2, TLR4 and TLR9 
genes in recipients of allogeneic haematopoietic stem cell transplant and susceptibility to 
infections caused by cytomegalovirus and filamentous fungi. A significant association was 
observed between the presence of allele C on the T-1237C polymorphism (TLR9) and 
susceptibility to viral pneumonia (p=0.02; OR, 2.83). For fungi, a significant association was 
observed between the presence of allele G on the Asp299Gly polymorphism (TLR4) and fungal 
colonization (p=0.02; OR, 7.5). However, susceptibility to fungal infections, predominantly fungal 
pneumonia, was instead significantly decreased in the presence of allele G on the Asp299Gly 
polymorphism (p=0.01; OR, 0.19). Thus, fungal colonization may not predict susceptibility to 
infection in the presence of this SNP. The finding that defective viral but not fungal sensing may 
predict susceptibility to infections highlights the divergent function of TLRs in the pathogenesis of 
opportunistic infections. 
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INTRODUCTION 
 
 Haematopoietic stem cell transplantation (HSCT) is an important option in the 
management of many haematological disorders (Welniak et al., 2007). However, although 
significant advances have been made in donor-recipient matching, conditioning regimens and 
post-transplant immunosuppressive therapy, HSCT is associated with a risk of complications that 
include graft-versus-host disease (GvHD) and viral (cytomegalovirus) or fungal (mainly Aspergillus 
spp.) infection (Cappellano et al., 2007; Pagano et al., 2007). The finding that only a fraction of 
patients with similar degrees of immunosuppression develop infection suggests that other, yet to 
be defined factors, contribute to susceptibility to infections. Recent studies have shown the 
association between polymorphic features of non-HLA cytokine encoding genes and the incidence 
and severity of post-transplant complications in the recipients of allogeneic HSCT, implying that 
the donor-recipient genotyping, extended for immune response loci, may be of prognostic value 
for the transplantation outcome (Bogunia-Kubik et al., 2006; Chen et al., 2006; Mayor et al., 
2007). 
There is growing evidence that variations within the genes of the family of innate immune 
receptors may account in part for the inherited differences in infectious disease susceptibility 
(Schroder and Schumann, 2005; Schwartz and Cook, 2005). The Toll-like receptor (TLR) family 
regulates both innate and adaptive immune responses (Akira et al., 2006). Given its broad effect 
on immunity, the function of TLRs in various human diseases has been investigated largely by 
comparing the incidence of disease among individuals with different polymorphisms in the genes 
that participate in TLR signalling. Growing amounts of data suggest that the ability of certain 
individuals to respond properly to TLR ligands may be impaired by single nucleotide 
polymorphisms (SNPs) within TLR genes, resulting in an altered susceptibility to, or course of, 
infectious or inflammatory disease (Lasker and Nair, 2006; Lazarus et al., 2002). Two 
polymorphisms in the coding region of TLR2, which attenuate receptor signalling, enhance the 
risk of acute severe infections, tuberculosis, and leprosy (Texereau et al., 2005). For TLR9, 
although it is highly conserved across species, differences in optimal stimulatory motifs imply 
that genetic variation could play a role in human diseases associated with altered innate immune 
responses (Krieg, 2006; Vollmer, 2006). The TLR9 SNP, T-1237C, located within the putative 
promoter region of the TLR9 gene, has been implicated in chronic inflammatory diseases such as 
asthma (Lazarus et al., 2003) and Crohn’s disease (Torok et al., 2004). 
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Most studies, however, have focused on the highly polymorphic TLR4 gene which 
encodes the receptor recognizing bacterial lipopolysaccharide (LPS). Two cosegregating missense 
polymorphisms affecting the extracellular domain have been identified in the TLR4 gene at minor 
allele frequencies between 8 and 10% in Caucasian populations (Lorenz et al., 2001b), which 
result, respectively, in aspartic acid to glycine substitution at position 299 (Asp299Gly) and 
threonine to isoleucine substitution at position 399 (Thr399Ile) in the receptor protein. These 
polymorphisms have been linked with blunted airway (Arbour et al., 2000) and systemic 
inflammatory responses (Michel et al., 2003) to inhaled LPS in adults and attenuated LPS-
induced responses in primary airway epithelial cells (Arbour et al., 2000). However, these SNPs 
seem to protect from atherosclerosis and related diseases (Li and Sun, 2007) and, regarding the 
Asp299Gly SNP, from malaria (Ferwerda et al., 2007). 
While reinforcing the role of TLRs in immunity and host resistance to fungi (Romani, 
2004), clinical evidence suggest that SNPs in selected TLR genes are associated with 
susceptibility to fungal infections (Morre et al., 2002; Van der Graaf et al., 2006), including in 
HSCT, where recipient but not donor SNPs were associated with susceptibility to invasive 
aspergillosis (Kesh et al., 2005). Given the role of innate immunity in the overall immune 
reconstitution after HSCT (Chen et al., 2006; Land, 2007), including rebuilding of antimicrobial 
immunity, genetic variations in innate immunity genes could have a major impact on microbial 
detection and ensuing immune response. 
In the present case-control study, we investigated the contribution made by selected 
polymorphisms in TLR2, TLR4 and TLR9 genes to susceptibility to fungal or viral infection in 
patients undergoing HSCT. 
 
 
MATERIALS AND METHODS 
 
 Study population. A total of 65 patients were included in the study, with males and 
females equally distributed. Mean age (±SD) was 41.0 (±16.1) years. Diagnoses of 
haematological disease included aplastic anaemia (n=1), acute lymphoblastic leukaemia (n=10), 
acute myeloid leukaemia (n=33), chronic lymphoid leukaemia (n=2), Hodgkin lymphoma (n=8), 
non-Hodgkin lymphoma (n=6), and multiple myeloma (n=5). Patients were recruited from a 
cohort of patients attending the Haematopoietic Stem Cell Transplant Unit, Section of 
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Haematology and Immunology, Department of Clinical and Experimental Medicine, University of 
Perugia, Italy. After signing informed consent, DNA was extracted as described (Carvalho et al., 
2007) from 5-10 ml of peripheral blood from patients after full chimerism was documented (a 
month after stem cell infusion) (Aversa et al., 1998). Donors were HLA-identical siblings in 28 
patients and one-haplotype mismatched family members in the others. Graft processing and 
transplantation procedure was previously described (Aversa et al., 1998; Aversa et al., 2005; 
Tabilio et al., 1997). 
 
 Microbiological evaluation. Patients were monitored for fungal colonization twice 
weekly, after transplant. Positive fungal cultures (39 patients) referred to positive tests on 
specimens from blood, bronchial alveolar lavage, sputum, stool, urine and catheter tips and no 
report of negative results for repeated tests on specimen from the same site. Aspergillus 
fumigatus (n=31), Aspergillus niger (n=3), Penicillium spp. (n=3), Fusarium solanii (n=1) and 
Rhyzopus oryzae (n=1) were among fungal species isolated. According to our standard practice, 
cytomegalovirus (CMV) pp65 antigenaemia and Immediate Early Antigen detection by 
immunofluorescence (CINA kit, Argene Biosoft, Varilhes, France) and real-time PCR (COBAS 
Amplicor CMV Monitor test, Roche Diagnostics, Branchburg, NJ, USA) assays were routinely 
performed 1 or 2 times a week during the first 6 post-transplant months in CMV-seropositive 
recipients (Aversa et al., 2005). If any signs or symptoms were present, CMV disease was 
diagnosed. 
 
 Clinical evaluation. Clinical evaluation of fungal or viral infection was accomplished by 
clinical parameters as well as by computerized tomographic and magnetic resonance imaging 
diagnostics. Twenty five out of 39 patients developed fungal infections including pneumonia by A. 
fumigatus (n=18), A. niger (n=1) and R. oryzae (n=1); sinusitis by A. fumigatus (n=2), and F. 
solanii (n=1); invasive infection by A. niger (n=1) and encephalitis by A. fumigatus (n=1). 
 
 Genotyping of TLR2, TLR4 and TLR9 polymorphisms. Genotype determination of 
polymorphisms in TLR2 (Arg677Trp and Arg753Gln), TLR4 (Asp299Gly and Thr399Ile) and TLR9 
(T-1923C, T-1486C, T-1237C, G1174A and G2848A) were performed using bi-directional PCR 
amplification of specific alleles (Bi-PASA) (Carvalho et al., 2007). Primer design, PCR 
amplification and cycling were done as described (Carvalho et al., 2007; Carvalho et al., 2008). 
  71 
The results obtained for the genotype of the study groups by Bi-PASA were further validated by 
sequencing analysis of 10 randomly selected samples. 
 
 Statistical analysis. The Fisher exact test and Pearson χ2 test were used to compare 
allele frequencies between patient groups and controls. Consistency of genotype frequencies with 
the Hardy–Weinberg equilibrium was tested using a χ2 test on a contingency table of observed vs. 
predicted genotype frequencies. χ2 values, odds ratios, and p values were calculated with 95% 
confidence intervals. 
 
 
RESULTS 
 
To study the possible association of the different TLR polymorphisms with susceptibility 
to cytomegalovirus (CMV) infection, HSCT patients with and without clinical signs of viral infection 
were evaluated. Thirty three patients (50% of the studied group) showed signs of CMV infection 
that included pneumonia (n=24, 73% of infected patients), encephalitis (n=2, 6%), retinitis (n=1, 
3%) and Epstein-Barr virus (EBV) co-infection (n=6, 18%). No statistically significant differences 
between patients with or without viral infection were observed regarding TLR polymorphisms 
(Table 1). However, patients with viral infection had a significantly higher frequency of the C allele 
on T-1237C (TLR9) than patients without infection (28.7% vs. 12.5%, respectively; p=0.02; OR, 
2.83). 
Patients with (n=39) and without (n=26) positive fungal cultures were assessed for 
possible association between fungal growth and TLR2, TLR4 and TLR9 polymorphisms. A 
comparison of allele frequencies and genotype distribution of the TLR9 and TLR2 polymorphisms 
revealed no statistically significant differences between patients with positive or negative fungal 
cultures. Although patients with positive fungal cultures had a higher frequency of the C allele on 
T-1486C (26.8% vs. 16.4%), allele A on G1174A (32.8% vs. 25.9%) and on G2848A (31.6% vs. 
25.9%) regarding TLR9 compared to patients with negative fungal cultures, these differences did 
not reach statistical significance (p=0.36 for C allele, and p=0.68 and p=0.80 for allele A of 
G1174A and G2848A, respectively) (Table 2). In contrast, patients with positive fungal cultures 
had a significantly higher frequency of allele G on Asp299Gly (TLR4) than patients with negative 
culture (12.8% vs. 2.0%, respectively; p=0.02; OR, 7.5) (Table 2). 
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Table 1. Genotype and allele frequencies of polymorphisms in TLR9, TLR4 and TLR2 genes in HSCT patients with and without clinical signs of viral infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE. OR, odds ratio; χ2 and p values were calculated regarding allele frequencies. 
 
 
Gene, SNP 
Study groups 
(n) 
Genotype 
n (%frequency) 
Allele 
n (% frequency) 
χ2 p value OR 
TLR9          
A-1923C  A/A A/C C/C A C    
 No viral infection (32) 31 1 0 (0.0) 63 (98.5) 1 (1.5)    
 Viral infection (33) 30 (91.0) 3 (9.0) 0 (0.0) 63 (95.5) 3 (4.5) 0.97 0.32 3.00 
          
T-1486C  T/T T/C C/C T C    
 No viral infection (32) 18 13 1 49 (77.5) 15 (22.5)    
 Viral infection (33) 24 (73.0) 8 (24.0) 1 (3.0) 56 (85.0) 10 (15.0) 1.44 0.23 0.58 
T-1237C          
 No viral infection (32) 24 (75.0) 8 (25.0) 0 (0.0) 56 (87.5) 8 (12.5)    
 Viral infection (33) 16 (48.6) 15 (45.4) 2 (6.0) 47 (71.3) 19 (28.7) 5.24 0.02 2.83 
          
G1174A  G/G G/A A/A G A    
 No viral infection (32) 16 (50.0) 16 (50.0) 0 (0.0) 48 (76.0) 16 (24.0)    
 Viral infection (33) 15 (46.0) 17 (51.0) 1 (3.0) 47 (71.5) 19 (28.5) 0.24 0.62 1.21 
G2848A          
 No viral infection (32) 17 (53.5) 12 (37.2) 3 (9.3) 46 (73.0) 18(27.0)    
 Viral infection (33) 19 (58.0) 12 (36.0) 2 (6.0) 50 (75.8) 16 (24.2) 0.25 0.61 0.82 
TLR4  A/A A/G G/G A G    
Asp299Gly          
 No viral infection (32) 25 7 0 (0.0) 57 (89.5) 7 (10.5)    
 Viral infection (33) 29 (88.0) 4 (12.0) 0 (0.0) 62 (94.0) 4 (6.0) 1.00 0.31 0.53 
TLR2  G/G G/A A/A G A    
Arg677Trp          
 No viral infection (32) 32 (100.0) 0 (0.0) 0 (0.0) 64 (100.0) 0 (0.0)    
 Viral infection (33) 33 (100.0) 0 (0.0) 0 (0.0) 66 (100.0) 0 (0.0) 0.00 0.98 0.97 
Arg753Gln          
 No viral infection (32) 32 (100.0) 0 (0.0) 0 (0.0) 64 (100.0) 0 (0.0)    
 Viral infection (33) 30 (91.0) 3 (9.0) 0 (0.0) 63 (95.5) 3 (4.5) 0.97 0.32 3.00 
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Table 2. Genotype and allele frequencies of polymorphisms in TLR9, TLR4 and TLR2 genes in HSCT patients with negative or positive fungal cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE. OR, odds ratio; χ2 and p values were calculated regarding allele frequencies. 
Gene, SNP 
Study groups 
(n) 
Genotype 
n (%frequency) 
Allele 
n (% frequency) 
χ2 p value OR 
TLR9          
A-1923C  A/A A/C C/C A C    
 Negative fungal culture (26) 24 (92.4) 2 (7.6) 0 (0.0) 50 (95.0) 2 (5.0)    
 Positive fungal culture (39) 37 (95.0) 2 (5.0) 0 (0.0) 76 (98.8) 2 (1.2) 0.17 0.67 0.65 
          
T-1486C  T/T T/C C/C T C    
 Negative fungal culture (26) 18 (69.6) 8 (30.4) 0 (0.0) 44 (83.6) 8 (16.4)    
 Positive fungal culture (39) 24 (62.5) 13 (32.5) 2 (5.0) 61 (73.2) 17 (26.8) 0.62 0.36 1.53 
T-1237C          
 Negative fungal culture (26) 14 (62.0) 10 (30.4) 2 (7.6) 38 (72.2) 14 (27.8)    
 Positive fungal culture (39) 26 (67.5) 13 (32.5) 0 (0.0) 65 (78.0) 13 (22.0) 1.99 0.15 0.54 
          
G1174A  G/G G/A A/A G A    
 Negative fungal culture (26) 14 (62.0) 11 (34.2) 1 (3.8) 39 (74.1) 13 (25.9)    
 Positive fungal culture (39) 17 (45.0) 22 (55.0) 0 (0.0) 56 (67.2) 22 (32.8) 0.16 0.68 1.18 
G2848A          
 Negative fungal culture (26) 14 (62.0) 11 (34.2) 1 (3.8) 39 (74.1) 13 (25.9)    
 Positive fungal culture (39) 22 (57.5) 13 (32.5) 4 (10.0) 57 (68.4) 21 (31.6) 0.06 0.80 1.11 
TLR4          
Asp299Gly  A/A A/G G/G A G    
 Negative fungal culture (26) 25 (96.1) 1 (3.9) 0 (0.0) 51 (98.0) 1 (2.0)    
 Positive fungal culture (39) 29 (74.3) 10 (25.2) 0 (0.0) 68 (88.0) 10 (12.8) 4.78 0.02 7.5 
TLR2  G/G G/A A/A G A    
Arg677Trp          
 Negative fungal culture (26) 26 (100.0) 0 (0.0) 0 (0.0) 52 (100.0) 0 (0.0)    
 Positive fungal culture (39) 39 (100.0) 0 (0.0) 0 (0.0) 78 (100.0) 0 (0.0) 0.08 0.77 0.66 
Arg753Gln          
 Negative fungal culture (26) 24 (92.4) 2 (7.6) 0 (0.0) 50 (95.0) 2 (5.0)    
 Positive fungal culture (39) 38 (97.5) 1 (2.5) 0 (0.0) 77 (92.4) 1 (8.0) 0.91 0.34 0.32 
  
74 
 
 
Table 3. Genotype and allele frequencies of polymorphisms in TLR9, TLR4 and TLR2 genes in HSCT patients with or without clinical signs of fungal infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE. OR, odds ratio; χ2 and p values were calculated regarding allele frequencies. 
Gene, SNP 
Study groups 
(n) 
Genotype 
n (%frequency) 
Allele 
n (% frequency) 
χ2 p value OR 
TLR9          
A-1923C  A/A A/C C/C A C    
 No fungal infection (14) 14 (100.0) 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0)    
 Fungal infection (25) 23 (92.0) 2 (8.0) 0 (0.0) 48 (96.0) 2 (4.0) 0.53 0.46 2.25 
          
T-1486C  T/T T/C C/C T C    
 No fungal infection (14) 7 (50.0) 7 (50.0) 0 (0.0) 21 (75.6) 7 (24.4)    
 Fungal infection (25) 17 (68.0) 6 (24.0) 2 (8.0) 40 (80.0) 10 (20.0) 0.26 0.60 0.75 
T-1237C          
 No fungal infection (14) 9 (64.29 5 (35.8) 0 (0.0) 23 (82.2) 5 (18.7)    
 Fungal infection (25) 17 (68.0) 6 (32.0) 0 (0.0) 40 (84.0) 8 (16.0) 0.04 0.83 0.88 
          
G1174A  G/G G/A A/A G A    
 No fungal infection (14) 7 (50.0) 7 (50.0) 0 (0.0) 21 (75.6) 7 (24.4)    
 Fungal infection (25) 10 (40.0) 15 (60.0) 0 (0.0) 35 (70.0) 15 (30.0) 0.22 0.63 1.29 
G2848A          
 No fungal infection (14) 7 (50.0) 5 (35.5) 2 (14.5) 19 (67.9) 9 (32.1)    
 Fungal infection (25) 15 8 (32.0) 2 (8.0) 38 (76.0) 12 (24.0) 0.60 0.43 0.67 
TLR4  A/A A/G G/G A G    
Asp299Gly          
 No fungal infection (14) 7 (50.0) 7 (50.0) 0 (0.0) 21 (75.6) 7 (24.4)    
 Fungal infection (25) 22 (88.0) 3 (12.0) 0 (0.0) 47 (94.0) 3 (6.0) 5.80 0.01 0.19 
TLR2  G/G G/A A/A G A    
Arg677Trp          
 No fungal infection (14) 14 (100.0) 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0)    
 Fungal infection (25) 25 (100.0) 0 (0.0) 0 (0.0) 50 (100.0) 0 (0.0) 0.18 0.67 0.55 
Arg753Gln          
 No fungal infection (14) 14 (100.0) 0 (0.0) 0 (0.0) 28 (100.0) 0 (0.0)    
 Fungal infection (25) 24 (96.0) 1 (4.0) 0 (0.0) 49 (98.0) 1 (2.0) 0.18 0.67 0.55 
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Within the first month after transplant, 25 of the 39 patients with positive fungal culture 
developed fungal infections. No significant differences in the TLR9 and TLR2 polymorphisms 
between the two groups of patients (infected and non-infected) were observed. Even though a 
lower frequency of the A allele on G2848A (TLR9) was observed in patients with infection (24.0% 
vs. 32.1%, with and without infection, respectively), this difference did not reach statistical 
significance (p=0.43). Interestingly, the frequency of allele G on Asp299Gly SNP in TLR4 was 
significantly lower in infected than non-infected patients (6.0% vs. 24.4%, respectively; p=0.01; 
OR, 0.19) (Table 3). Thus, the same TLR4 polymorphism was associated with increased fungal 
colonization but decreased susceptibility to infection. 
 
 
DISCUSSION 
 
 Given that TLR polymorphisms are associated with susceptibility to infection in a 
pathogen-specific manner (Schroder and Schumann, 2005; Schwartz and Cook, 2005), 
polymorphisms in these receptors could represent risk factors for infections in HSCT. The results 
of the present study show that distinct TLR SNPs are indeed associated with susceptibility to viral 
or fungal infection. TLR9 is critically required in the process of cytomegalovirus (CMV) sensing 
(Bozza et al., 2007; Tabeta et al., 2004) to assure rapid antiviral responses, coordinated with 
other TLR-dependent and –independent events that are required to establish adaptive immunity 
(Delale et al., 2005). We found that the C allele on T-1237C was highly predictive of susceptibility 
to CMV infection. As this SNP is associated with altered TLR9 expression (Novak et al., 2007), 
our findings confirm the importance of the viral detection system for the activation of antiviral 
immune resistance. As a matter of fact, we have recently found that the exploitation of TLR9 as 
adjuvant receptor may provide new options for optimizing anti-CMV therapeutic strategies in 
experimental transplantation (Bozza et al., 2007). 
 Although the TLR9 SNPs tested tended to have a higher frequency in patients with 
positive fungal cultures and a lower frequency of the A allele on G2848A was observed in 
patients without infection, either the limited sample size might have reduced the power of the 
study, therefore increasing the chance for false-negative results, or TLR9 may be of secondary 
importance in fungal infections. In this regard, in addition to the fact that A. nidulans (and 
probably A. fumigatus) has been shown to be virtually devoid of genomic cytosine methylation 
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(Antequera et al., 1984), TLR9 has been found to exert control over allergy to the fungus more 
than infection (Bellocchio et al., 2004a; Grohmann et al., 2007). Accordingly, TLR9 SNPs have 
been associated with an increased risk of asthma (Lazarus et al., 2003) and allergic 
bronchopulmonary aspergillosis (Carvalho et al., 2008), and TLR9 antagonists are under 
development for patients with asthma and other allergic conditions (Sun et al., 2007). 
 We observed no association between polymorphisms in TLR2 and susceptibility to either 
viral or fungal infections, despite the fact that the Arg753Gln polymorphism has been associated 
with CMV replication and disease after liver transplantation (Kijpittayarit et al., 2007). In contrast, 
the results of the present study are similar to those obtained in haematopoietic transplanted 
patients with invasive aspergillosis (Kesh et al., 2005). As TLR2-deficient mice are highly 
susceptible to experimental ABPA (L. Romani, unpublished observations) more than Aspergillus 
pulmonary infection (Bellocchio et al., 2004a), our results are consistent with a crucial role for 
TLR2 in allergy (Vanhinsbergh et al., 2007) and lung inflammation (Dessing et al., 2008). 
One interesting result of the present study concerns the intriguing role for TLR4 in the 
recognition and initiation of the inflammatory response to Aspergillus. Experimental evidence 
indicates TLR4 as one of the most important innate immune pathways in response to the fungus 
(Bellocchio et al., 2004a; Braedel et al., 2004; Chignard et al., 2007; Mambula et al., 2002; 
Netea et al., 2003). Accordingly, we have recently found that the Asp299Gly polymorphism is 
highly associated with chronic cavitary pulmonary aspergillosis (Carvalho et al., 2008). In the 
present study, we found a positive association between the Asp299Gly polymorphism and fungal 
colonization but not susceptibility to infection, confirming the previously observed lack of 
association of this SNP with aspergillosis in allogeneic stem cell transplantation (Kesh et al., 
2005). The positive association of this SNP with fungal colonization could be explained by the 
fact that the presence of an abnormal TLR4 extracellular domain may hamper its function by 
disrupting microbial recognition, eventually leading to fungal escape from immunosurveillance. 
However, this polymorphism has also been shown to have a protective effect in other infectious 
diseases, such as malaria (Ferwerda et al., 2007), in hyper-inflammatory states, such as 
atherosclerosis (Li and Sun, 2007), and to be associated with longevity (Candore et al., 2006). 
Therefore, the failure to recognize the fungus may be compensated by the lack of an exuberant 
inflammatory response to it which may ultimately be harmful to the host. In this regard, we have 
recently found that a hyper-inflammatory state, more than the fungus itself, may contribute to 
susceptibility to aspergillosis and other fungal infections (Romani and Puccetti, 2007). 
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Paradoxically, the ability to restrain antifungal inflammation pointed to novel strategies for 
immune therapy that attempted to limit inflammation in order to stimulate an effective antifungal 
immune protection (Romani et al., 2008; Romani and Puccetti, 2007). Thus, by limiting the 
inflammatory response to the fungus, the Asp299Gly polymorphism could contribute to 
resistance to infection, despite evidence of fungal growth. 
 In candidiasis, resistance to infection with limited inflammatory response occurred upon 
the engagement of the Toll/IL-1 receptor (TIR) domain-containing adaptor protein inducing IFN 
(TRIF)-dependent pathway downstream TLR4 (De Luca et al., 2007). This resulted in the 
generation of “protective tolerance to the fungus”, a homeostatic condition in which host immune 
defence mechanisms of protection are provided without necessarily eliminating fungal pathogens 
but with acceptable levels of inflammatory pathology and tissue damage (Romani and Puccetti, 
2006). Whether and how the Asp299Gly polymorphism impairs fungal recognition and at the 
same time limits the host inflammatory response to it is presently under investigation. It is worth 
to anticipate here that, similar to candidiasis, the TRIF pathway also pivotally controls pathogenic 
inflammation to Aspergillus in experimental HSCT (L. Romani, unpublished observations). 
Collectively, these results add to the current knowledge of the importance of TLRs in 
infections in HSCT. While CMV infection was significantly associated with altered TLR9 
expression, Aspergillus colonization but not infection was significantly associated with defective 
TLR4-dependent recognition, a finding suggesting that fungal infection and associated 
inflammatory disease may occur in a pathogen-autonomous manner. This will fit with the new 
emerging role of the innate immunity that is its role in sterile inflammation – inflammation 
caused by endogenous TLR ligand activation (Trinchieri and Sher, 2007). Therefore, despite that 
the sample size could not allow the precise appreciation of some associations, the results of the 
present study strongly point to the intricacies between pathogens and host immune responses in 
the setting of haematopoietic transplantation. 
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ABSTRACT 
 
Non-Hodgkin lymphoma (NHL) includes a set of heterogeneous lymphoproliferative 
malignancies often associated with altered immunological functions of the host and chronic 
inflammatory type of infections. Toll-like receptors, namely TLR9, has been shown to be 
associated with both autoimmune and chronic inflammatory type of diseases. Herein, we show 
that a polymorphism in the promoter region of TLR9 – T-1237C – associates with an increased 
incidence of NHL. This polymorphism introduces a novel regulatory site that is trans-activated by 
the IL-6-dependent transcription factor IL-6 RE-BP, thus resulting in increased expression of 
TLR9. Cells harbouring the mutant allele have a higher expression of the TLR9 gene, which is 
markedly increased upon receptor activation by ligand binding. TLR9 activation in B lymphocytes 
sequentially leads to increased proliferation rates of these cells, as well as higher production of 
IL-6, resulting in a TLR9 activation loop leading to B lymphocyte-specific uncontrolled 
proliferation. Taken together, our observations suggest that the T-1237C polymorphism confers 
host predisposition to NHL by increased cellular proliferation, making B lymphocytes more 
susceptible to acquire transforming mutations associated with the development of NHL. Our 
data, showing that the T-1237C polymorphism in the TLR9 promoter leads to an increased TLR9 
expression under the influence of the pro-inflammatory cytokine IL-6, has important implications 
on the usage of CpG agonists on several therapeutic strategies.  
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INTRODUCTION 
 
 Non-Hodgkin lymphoma (NHL) is a haematological disease responsible for a large 
number of cancer-related deaths. NHL includes a heterogeneous group of malignant 
lymphoproliferative diseases whose incidence has substantially increased over the past decades 
in western countries (Parkin, 2001). Genetic and environmental factors underlying an altered 
immunological function are the best characterized and known risk factors for NHL, although its 
aetiology and the underlying causes for the observed increase are largely unknown (Baris and 
Zahm, 2000). Individuals with immune deficiencies associated with immune suppressive therapy 
after transplantation, human immunodeficiency virus (HIV) infection and congenital conditions 
are among those with higher incidence rates of lymphoid malignancies (Beral et al., 1991; 
Filipovich et al., 1992). Additionally, clinical and experimental data consistently associated 
several autoimmune and chronic inflammatory disorders, including rheumatoid arthritis and 
systemic lupus erythematosus, with an increased risk of NHL (Grulich et al., 2007). Some NHL 
subtypes have also been linked with specific infectious agents including Helicobacter pylori and 
several viruses, namely Epstein-Barr virus (Muller et al., 2005). 
Although the immunological status of the host is considered one of the major 
determinants in NHL development, not much is known about this subject. A recent large scale 
evaluation of polymorphisms in immune and inflammatory genes reinforced the idea that 
variations in genes related to immune function may predispose to the development of NHL 
(Cerhan et al., 2007). Genetic variants in tumour necrosis factor (TNF) and interleukin-10 (IL10), 
key cytokines involved in the inflammatory response and immune balance, were shown to 
increase the risk of NHL and influence the clinical course of the disease (Bogunia-Kubik et al., 
2008; Rothman et al., 2006). In addition, experimental evidence also supports a role for variants 
in cytotoxic T lymphocyte antigen 4 (CTLA4) in susceptibility to NHL (Monne et al., 2004; Piras et 
al., 2005). More recently, a functional variant in the gene encoding for the costimulatory 
molecule CD40, associated with reduced circulating levels of the protein and lower CD40 surface 
expression by dendritic cells, was also proposed as risk factor for non-Hodgkin lymphoma, in 
particular follicular lymphoma (Skibola et al., 2008). 
However, in recent years, considerable attention has focused on the importance of innate 
immunity, the first line of defence which differentiates self from non-self and activates the 
adaptive immune system through specific signals (Fearon and Locksley, 1996; Medzhitov and 
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Janeway, 1997). The innate immune system is able to recognize conserved molecular motifs in 
pathogens through pattern recognition receptors, including Toll-like receptors (TLRs). TLRs 
mediate the recognition of microbial challenges and the subsequent inflammatory responses 
through rapid changes in the expression of genes encoding cytokines and inflammatory 
molecules (Akira et al., 2001). Several genetic variants in TLRs have already been characterized 
regarding susceptibility to infectious and inflammatory diseases (Schroder and Schumann, 
2005). The first report linking TLRs and susceptibility to cancer showed that a polymorphism in 
TLR4 - Asp299Gly - predisposed to gastric mucosa-associated lymphoid tissue (MALT) lymphoma 
(Hellmig et al., 2005). However, the extent to which genetic variants in TLRs increase the risk of 
NHL is still unknown. 
TLR-mediated recognition of microbial stimuli often leads to the activation of innate 
immune cells, including B lymphocytes (Akira et al., 2001; Iwasaki and Medzhitov, 2004). These 
cells are known to have a TLR repertoire in which TLR9, a receptor that detects unmethylated 
CpG motifs prevalent in bacterial and viral DNA, predominates (Bourke et al., 2003; Hemmi et 
al., 2000). The T-1237C polymorphism, located within the putative promoter region of the TLR9 
gene, has already been shown to predispose to several autoimmune and chronic inflammatory 
conditions, including asthma, Crohn’s disease and systemic lupus erythematosus (Demirci et al., 
2007; Lazarus et al., 2003; Torok et al., 2004). Additionally, viral infections and their persistent 
antigen-driven immune receptor activation also support a role for chronic stimulation in the clonal 
evolution of virus-associated NHL (Ivanovski et al., 1998). The involvement of TLR9, not only in 
chronic inflammatory disorders, but also in viral recognition, suggests that the T-1237C 
polymorphism may have a major impact in NHL, often concurrent with the development of 
chronic inflammatory pathologies as well as viral infection. 
Taking all these observations into account, we hypothesized that the presence of the T-
1237C polymorphism in the TLR9 gene could confer susceptibility to NHL. We show that the 
polymorphism associates with NHL, by introducing a new regulatory site responsive to an IL-6-
dependent transcription factor. 
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MATERIALS AND METHODS 
 
Study populations. The case population consisted of 252 non-Hodgkin lymphoma 
(NHL) patients (mean age=55.0±16.2; 55.6% males, 44.4% females) of Portuguese origin. These 
patients were recruited from hospitals and office-based physicians involved in the diagnosis and 
treatment of lymphoma. For 147 patients, the disease was classified in its subtypes; for subtype-
specific analysis, only follicular lymphoma, FL (n=68, 46.3%), and diffuse large B cell lymphoma, 
DLBCL (n=35, 23.8%), were considered. Patients who had a history of transplantation or human 
immunodeficiency virus (HIV) infection were excluded from the study. The control population 
consisted of 789 unrelated healthy blood donors frequency-matched to patients by age within 5 
years, sex and country of origin. Study protocols were approved by each institution’s ethic review 
committee. All study participants provided written informed consent prior to biospecimen 
collection. 
 
Determination of T-1237C genotype. Genomic DNA was extracted from leucocytes 
with the NucleoSpin Blood DNA isolation kit (Macherey-Nagel, Düren, Germany). Determination of 
the T-1237C genotype (SNP id: rs5743836) was performed using bi-directional PCR amplification 
of specific alleles (Bi-PASA), as previously described (Carvalho et al., 2007). 
 
Analysis of TLR9 promoter region. The promoter sequence in the vicinity of the T-
1237C polymorphism site was analyzed in order to predict and compare potential transcription 
factor binding sites in relation to the genotype at the -1237 nucleotide position. Analysis was 
performed in 100% matrix to sequence homology by using the Transcription Element Search 
System (TESS) interface. The parameters used in the prediction of transcription factor binding 
motifs included La, the log-likelihood score, and Lq, a measure of the goodness-of-fit of the DNA 
sequence to the consensus binding motif, calculated by dividing La by the maximum La possible 
for the TESS interface; the best possible Lq value was 1.000. 
 
Plasmid constructs and mutagenesis. The plasmid vector containing the luciferase 
gene under the control of the wild-type TLR9 promoter (pGL3-hTLR9-T) was a generous gift from 
Dr. Fumihiko Takeshita (Takeshita et al., 2004). The plasmid was used to perform site-directed 
PCR mutagenesis. Briefly, the single nucleotide substitution at position -1237 in the 5’-flanking 
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region was introduced by PCR amplification using the forward primer 5’-
TATGAGACTTGGGGGAGTTTCCAGGCAGAGGGAACAGCACA-3’ and the reverse primer 5’-
TGTGCTGTTCCCTCTGCCTGGAAACTCCCCCAAGTCTCATA-3’. An all-round PCR amplification was 
performed in a 20 μl volume that included autoclaved ultra-filtered water, 1× PCR buffer, 200 μM 
dNTP mixture, 2.5 μM primers, 2.5 U of Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA, 
USA) and approximately 200 ng of plasmid template. The PCR product was then digested with 
DpnI, removing methylated parental template, and cloned in Escherichia coli. Transformants 
carrying the plasmid vector with the luciferase gene under the control of the mutant TLR9 
promoter (pGL3-hTLR9-C) were selected using Bi-PASA (Carvalho et al., 2007). The promoter 
region of selected transformants was then amplified and sequenced to confirm the correct base 
substitution. 
 
Cell lines and cell culture. The Raji cell line (human B lymphocytes derived from 
Burkitt’s lymphoma) was purchased from ATCC (American Type Culture Collection, Manassas, 
VA). Cells were cultivated in RPMI culture medium [RPMI 1640 medium (Invitrogen, Carlsbad, 
CA, USA) with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES, 1.0 mM sodium pyruvate and 10% fetal bovine serum (FBS)] without 
antibiotics at 37ºC and 5% CO2. The medium was renewed every 2-3 days. 
 
Transient transfection and luciferase reporter gene assay. Raji cells (5×106 
cells/ml) cultured in RPMI medium were transfected using the Microporator system (NanoEnTek 
Inc, Seoul, Korea) with a 10 μl tip (pulse voltage of 1350 V and width of 30 ms) with 0.5 μg of 
the plasmid constructs. To normalize transfection efficiency, 0.5 μg of the control β-galactosidase 
vector (pCMV-βgal) were always co-transfected. Cells were then resuspended in antibiotic-free 
RPMI medium, seeded in 48-well plates and incubated for 24 hours. After recovery, human 
recombinant IL-6 was added to 1×106 cells (100 ng/μl) and cells were cultured for 12 hours. 
Cells were then lysed in 200 μl of 1× Passive Lysis Buffer (Promega, Madison, WI, USA) and 
luciferase activity in 10 μl aliquots of the cell lysates was measured using the Luciferase Assay 
System (Promega) according to the manufacturer’s instructions. Firefly luciferase activity was 
normalized against β-galactosidase activity, which was determined with the β-galactosidase 
Enzyme Assay System (Promega), according to the manufacturer’s instructions. Data are 
expressed in relative luciferase units, with the unit corresponding to the normalized luciferase 
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activity. All experiments were performed in triplicate and repeated at least in two different 
occasions. 
 
Peripheral blood mononuclear cell (PBMC) culture. PBMC were isolated using 
Histopaque-1077 (Sigma, St. Louis, MO, USA) according to the manufacturer’s instructions. After 
centrifugation, cells were resuspended in phosphate buffered saline (PBS) containing 0.5% bovine 
serum albumin (BSA) and 0.05% EDTA, and counted in a hemocytometer. The viability of cells 
was determined using trypan blue exclusion. Aliquots of 200 μl containing 1×106 PBMC were 
then seeded in 48-well flat bottom plates and cells were cultivated for 5 days in the presence of 
0.05 μM CpG ODN 2006 (5’-tcgtcgttttgtcgttttgtcgtt-3’) (InvivoGen, Toulouse, France) at 37ºC in a 
5% CO2 humidified atmosphere. Cells either unstimulated or stimulated with control CpG ODN 
2006 (5’-tgctgcttttgtgcttttgtgctt-3’) (InvivoGen) were included as controls throughout the study. 
 
CFSE proliferation assay. PBMC were resuspended at a concentration of 2.5×106 
cells/ml in serum-free Hank’s Balanced Salt Solution (HBSS) and labelled with 
carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR, USA) at a final 
concentration of 5 μM for 5 min at room temperature with occasional shaking. Labelling was 
quenched by the addition of 1/5 of the total volume of FBS 10%. Cells were then washed twice 
with in complete RPMI medium and resuspended at the concentration of 2×106 cells/ml before 
culturing in 24-well plates. Next, PBMC stimulated with CpG ODN for 5 days at 37ºC and 5% CO2 
were washed, resuspended in staining buffer (0.5% BSA, 0.04% EDTA, 0.05% sodium azide in 
PBS) and stained with APC-conjugated anti-human CD19 (Becton Dickinson, San Jose, CA, USA) 
for 15 min at room temperature in the dark and analyzed on a BD FACSCalibur flow cytometer 
(Becton Dickinson). 
 
Real-time RT-PCR. After the 5-day CpG ODN stimulation described above, total RNA 
was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. Total RNA (1 μg) was reverse-transcribed using the iScript cDNA 
Synthesis Kit (Bio-Rad, Marnes La Coquette, France). For RT-PCR, 1 μl of cDNA was used as 
template in a 20 μl reaction conducted using the QuantiTect Sybr Green PCR Kit (Qiagen) 
according to manufacturer’s instructions. Each sample was measured in triplicate. The RT-PCR 
primers used were as follows: β-actin, sense: 5'-GCCGTCTTCCCCTCCATCGTG-3', antisense: 5'-
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GGAGCCACACGCAGCTCATTGTAGA-3'; TLR9, sense: 5'-CAGCAGCTCTGCAGTACGTC-3', 
antisense: 5'-CTCAGGCCTTGGAAGAAGTG-3'. RT-PCR was conducted on a LightCycler System 
(Roche Applied Science, Basel, Switzerland) and the thermal cycling conditions included 50 
cycles of 10 s at 95 ºC, 20 s at 55 ºC, and 20 s at 72 ºC, after a 15-min initial step of enzyme 
activation at 95 ºC, a melting step of 55-95 ºC (0.5 ºC/s) and a final cooling step at 40 ºC. 
Expression of β-actin was used as an internal control for all of the samples. Expression of TLR9 is 
indicated as n-fold increase relative to the level of TLR9 expression in untreated wild-type cells 
using the 2-ΔΔCt method, as described previously (Livak and Schmittgen, 2001). 
 
IL-6 quantification. IL-6 present in supernatants from PBMC cultures either in 
untreated conditions or stimulated for 5 days with CpG ODN 2006 was quantified using human 
IL-6 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) according to manufacturer’s 
instructions. 
 
Statistical analysis. Patients were analysed as all NHL and by the two major subtypes, 
FL and DLBCL. Fisher’s exact test and Pearson’s χ2 test were used to compare genotype 
frequencies between the patient groups and controls. Consistency of genotype frequencies with 
the Hardy–Weinberg equilibrium was tested using a χ2 test on a contingency table of observed 
versus predicted genotype frequencies. The values of χ2, odds ratio (OR) and p were calculated at 
95% confidence intervals (CI). Analyses were conducted using the SPSS 16.0 software. 
 
 
RESULTS 
 
The T-1237C polymorphism associates with risk of developing non-Hodgkin 
lymphoma (NHL). To determine whether there was an association of the T-1237C 
polymorphism with NHL, we analysed a population of 252 patients with different subtypes of the 
disease, the most frequent being follicular lymphoma (FL, n=68) and diffuse large B cell 
lymphoma (DLBCL, n=35). Genotype frequencies of control individuals (n=789) for the T-1237C 
polymorphism were in Hardy-Weinberg equilibrium (p>0.05). 
A comparison of genotype distribution of the T-1237C polymorphism between the 
controls and the total number of NHL patients revealed a significant association between the 
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presence of the C allele and development of this haematological malignancy (19.4% vs. 31.0%; 
p<0.001; odds ratio [OR], 1.86; 95% confidence interval (CI), 1.35-2.57) (Table 1). Moreover, 
this association occurs independently of the major NHL subtypes considered, FL (19.4% vs. 
30.9%; p<0.05; OR, 1.86, CI, 1.08-3.18) and DLBCL (19.4% vs. 37.1%; p<0.05; OR, 2.46, CI, 
1.22-4.93). No significant associations were found when considering other features of clinical 
value including international prognostic indexes (IPI and FLIPI), clinical stage of the disease and 
overall survival (data not shown). 
 
 
Table 1. Genotype distribution of the T-1237C polymorphism in the total number of non-Hodgkin lymphoma (NHL) 
patients, follicular lymphoma (FL) or diffuse large B cell lymphoma (DLBCL) subtypes, and controls 
 
SNP 
Study groups 
(n) 
Genotype 
n (% frequency) 
χ2 p value OR (95% CI)* 
 T/T T/C C/C T/C + C/C 
Controls (789) 636 (80.6) 144 (18.3) 9 (1.1) 153 (19.4) 
 
All NHL (252) 174 (69.0) 76 (30.2) 2 (0.8) 78 (31.0) 14.8 0.000 1.863 (1.354-2.565) 
FL (68) 47 (69.1) 21 (30.9) 0 (0.0) 21 (30.9) 5.11 0.028 1.857 (1.084-3.184) 
TLR9 
T-1237C 
DLBCL (35) 22 (62.9) 13 (37.1) 0 (0.0) 13 (37.1) 6.56 0.016 2.456 (1.225-4.929) 
 
* Odds ratio (OR), confidence interval (CI). χ2 and p values were calculated regarding presence of variant allele. 
 
 
TLR9 promoter activity is altered by the T-1237C polymorphism. The base 
substitution at nucleotide position -1237 was assessed for predicted effects on transcription 
factor-binding motifs. An in silico analysis of the TLR9 promoter using the TESS interface showed 
that the T-1237C polymorphism introduces a new potential regulatory transcription factor-binding 
motif for interleukin-6 (IL-6) response element (IL-6 RE) at position -1238 to -1234 with the 
consensus sequence TTCCAG. This IL-6 RE is a binding site for, and is trans-activated by the IL-6-
inducible IL-6 RE-binding protein (IL-6 RE-BP), suggesting an altered role of IL-6 in the regulation 
of the TLR9 gene in individuals harbouring this polymorphism. 
To explore the effect of the C allele on TLR9 gene expression in B lymphocytes, 3.2 kb of 
both the wild-type and the mutant human promoter sequence were placed upstream of a 
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luciferase reporter gene and the constructs were transiently expressed in human Raji B cells. 
Transient transfection assays with the use of these promoter-reporter constructs showed 
significantly lower transcriptional activity for the C allele construct in basal conditions (p<0.001) 
(Figure 1A). In contrast, recombinant human IL-6 stimulation increased the transcriptional 
efficiency for the mutant C allele by 3-fold as compared with the T allele (p<0.001). Moreover, 
the allele-specific transcription data also showed that the ratio of IL-6-stimulated to basal gene 
expression in the C allele was more than three times that in the T allele (p<0.001). These results 
indicate that the T-1237C polymorphism has a major influence on the transcriptional regulation 
of the TLR9 gene. 
 
 
 
Figure 1. IL-6 induces an increase in TLR9 expression in cells harbouring the mutant allele of the T-1237C 
polymorphism.  A. Luciferase reporter assay of human Raji B cells transfected with plasmid vectors containing the 
luciferase gene under the control of the wild-type or mutant TLR9 promoter. Cells (1×106 cells/ml) were transfected 
by electroporation and stimulated with IL-6 (100 ng/ml) for 12 h. Results shown are the means of relative luciferase 
activity units corrected to the transfection efficiency ± SD of at least three independent transfections B. Dose-
dependent stimulation of human PBMCs with different T-1237C genotypes by IL-6. Human PBMCs (1×106 cells/ml) 
were stimulated with IL-6 over the concentration range from 0 (addition of a neutralizing anti-IL-6 antibody) to 100 
ng/ml. Cells were harvested at 12 h and total RNA was isolated to determine TLR9 mRNA expression levels. Results 
shown are the means ± SD of at least six independent observations. 
 
 
IL-6 promotes an increase in TLR9 expression in cells harbouring the C 
allele. To analyze the previously observed effects of the T-1237C, peripheral blood mononuclear 
cells (PBMCs) were isolated from unrelated healthy blood donors with different T-1237C 
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genotypes and treated with increasing concentrations of recombinant human IL-6. Quantification 
of TLR9 mRNA expression showed that, in wild-type cells, no changes in TLR9 expression were 
observed either upon stimulation with different IL-6 concentrations or in the total absence of 
endogenous IL-6, achieved using a neutralizing anti-IL-6 antibody (Figure 1B). In contrast, cells 
carrying the C allele responded to the presence of IL-6 with an increased expression of TLR9 
(Figure 1B).  For the higher IL-6 concentrations tested, TLR9 expression values became very 
similar, suggesting a saturation-like behaviour in the response to IL-6. 
In normal conditions, with no addition of exogenous IL-6, nor neutralization of IL-6, cells 
carrying the C allele displayed an approximately 4-fold increase in basal transcript amount of 
TLR9 as compared with the T allele (Figure 2A). This higher basal expression of TLR9 was 
dependent on IL-6, as the addition of neutralizing anti-IL-6 antibody decreased the TLR9 
expression in cells with the C allele to levels similar to those displayed by their wild-type 
counterparts. 
We also wanted to investigate whether the natural ligand for TLR9 would modulate its 
expression and this modulation was different in wild-type or mutant cells. We observed that TLR9 
activation through CpG stimulation induced a strong increase in TLR9 expression in cells with the 
C allele, reaching more than a 5-fold increase as compared to wild-type cells (Figure 2A) 
(p<0.005). No significant differences in gene expression were observed in CpG ODN 2006-
stimulated cells with the wild-type genotype. Importantly, the CpG induction of TLR9 mRNA in 
mutant cells was dependent on IL-6, as the neutralization of this molecule abrogated the effect of 
IL-6. Simultaneous stimulation of cells with CpG ODN 2006 and the TLR9 antagonist CpG 
TTAGGG in a 1:2 ratio did not result in any variation in TLR9 expression from that displayed in 
the control conditions (p<0.005) (Figure 2A). 
 
The C allele underlies increased proliferation upon TLR9 activation. To 
evaluate whether the T-1237C polymorphism could affect CpG ODN 2006-induced B cell 
expansion in vitro, PBMCs with different T-1237C genotypes were CpG ODN 2006-stimulated and 
proliferation of CD19+ cells was assessed by monitoring the dilution of carboxyfluorescein 
succinimidyl ester (CFSE). CpG ODN 2006 concentrations ranging from 0.01 μM to 3 μM were 
tested and the optimal concentration of 0.05 μM was used (data not shown). 
Although a TLR9 overexpression was observed in untreated cells with the C allele, 
proliferation was not observed in untreated conditions for either genotype (Figure 2B). However, 
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in CpG ODN 2006-stimulated conditions, while wild-type CD19+ cell proliferation was moderately 
induced by CpG ODN (32.5% CFSElow cells), the proliferation was significantly higher in cells with 
the C allele (64.3%) (p<0.001). Stimulation with a control CpG ODN 2006 (without the normal 
stimulatory sequence) led to reduced proliferation, although always higher in cells harbouring the 
C allele (Figure 2B). 
The increase in the proliferation of CD19+ cells harbouring the C allele upon TLR9 
activation was shown to be IL-6-dependent since the addition of a neutralizing anti-IL-6 antibody 
was able to abrogate the effect of CpG ODN 2006 stimulation on cells carrying the C allele 
(Figure 2B). Moreover, increased proliferation displayed by cells with the mutant allele upon TLR9 
activation was also demonstrated as being TLR9-specific since simultaneous stimulation with 
CpG ODN 2006 and a known TLR9 antagonist (TTAGGG ODN) reverted proliferation to basal 
values for both alleles (Figure 2B). 
 
Cells harbouring the C allele display higher IL-6 production upon TLR9 
activation. To assess if the production of IL-6, one of the cytokines more abundantly secreted 
after TLR9 activation in B lymphocytes, was dependent on the T-1237C polymorphism, IL-6 was 
quantified in supernatants from PBMC cultures after 5-day stimulation with CpG ODN 2006 
(Figure 2C). The results show that CpG ODN 2006 stimulation resulted in a substantially higher 
IL-6 production by cells harbouring the C allele (156.4±49.4 pg/ml) as compared with cells 
carrying the wild-type promoter (44.2±17.0) (p<0.05), suggesting a direct correlation of the IL-6 
amount and cellular proliferation displayed by cells with the mutant allele (Figure 2C). 
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Figure 2. TLR9 activation of cells harbouring the mutant allele of the T-1237C polymorphism by CpG ODN 2006 
increases TLR9 gene expression, B cell proliferation and IL-6 secretion. A. TLR9 mRNA expression of human PBMCs 
with different T-1237C genotypes (1×106 cells/ml) treated in the following conditions for 5 days: untreated and 
stimulated with either CpG ODN 2006 (0.05 μM), anti-IL-6 antibody (1:10), CpG ODN 2006 and anti-IL-6 antibody, 
or CpG ODN 2006 together with the TLR9 antagonist CpG ODN TTAGGG in a 1:2 ratio. Results shown are the means 
± SD of at least six independent observations. B. Proliferation of CD19+ cells assessed by CFSE dilution in cultures of 
human PBMCs with different T-1237C genotypes (1×106 cells/ml) after treatment in the following conditions for 5 
days: untreated and stimulated with either CpG ODN 2006 (0.05 μM), CpG ODN 2006 control (0.05 μM), CpG ODN 
2006 and anti-IL-6 antibody (1:10) or CpG ODN 2006 and CpG ODN TTAGGG in a 1:2 ratio. Results shown are the 
means ± SD of at least twelve independent observations. C. Quantification of IL-6 in supernatants of cultures of 
human PBMCs with different T-1237C genotypes (1×106 cells/ml) either in untreated conditions or stimulated with 
CpG ODN 2006 (0.05 μM) for 5 days. Results shown are the means ± SD of at least six independent observations. 
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DISCUSSION 
 
Host genetic factors are emerging as key determinants of susceptibility to diseases of 
diverse aetiologies, including cancer. Identifying candidate genes is a major challenge that has to 
stem from a profound understanding of the pathophysiology of the disease. Recently, 
considerable attention has been given to genetic variations of genes of the innate immune 
system. While variations on these genes may be advantageous at the population level, allowing 
for a more intricate repertoire and enabling the host to withstand microbial challenges, there may 
be less favourable outcomes for individuals that harbour certain genotypes associated with 
excessive immune activation and inflammatory drive. 
TLRs are differentially expressed on a wide variety of tumours (Bourke et al., 2003), 
suggesting that they may play important roles in cancer biology. In fact, dynamic interaction 
between malignant cells and the innate immune system is essential for tumour survival, growth 
and metastasis (Yu and Chen, 2008). However, cancer cells are also under surveillance due to 
their recognition by immune cells as foreign, thus having to overcome such immune surveillance 
in order to progress. The importance of TLRs in cancer immunity is evident in an increasing 
number of reports showing that variants in these receptors are associated with cancer risk. More 
specifically, the aetiology of some lymphoma subtypes has been associated with polymorphisms 
in TLR1, -2, -4, -5 and -9 genes (Nieters et al., 2006). Our data clearly show an association 
between the T-1237C polymorphism in the promoter region of TLR9 and non-Hodgkin lymphoma 
(NHL), increasing the risk by more than 80% independently of the lymphoma subtype. 
The genetics of haematological malignancies in general is complex. Although there is 
often a well-recognized association between the immunodeficient status of the host and 
susceptibility to NHL, little is known about the cellular and molecular mechanisms leading to 
abnormal lymphocyte proliferation or how they are linked to the development of a particular NHL 
subtype. Our study indicates that TLR9, through its biological effects (e.g. cell survival, 
proliferation, and inflammation), may be contributing to the pathogenesis of NHL in a cell-specific 
manner. In this way, a deregulation of TLR9 expression and activity is suggested to directly 
contribute to the development of NHL through the induction of B lymphocyte-specific uncontrolled 
proliferation (Figure 3). In addition, the effect of the T-1237C polymorphism would not contribute 
to disease manifestation unless an underlying chronic stimulation of the immune system leading 
to a persistent activation of TLR9 was present. 
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Figure 3. Proposed model representing the effect of the T-1237C polymorphism in B lymphocyte activation and 
proliferation. TLR9 activation by its ligand, CpG DNA, induces the production of IL-6, which binding to its receptor, 
promotes translocation of the IL-6 response element binding protein (IL-6 RE-BP) to the nucleus. In cells harbouring 
the variant allele, the transcription factor will bind the IL-6 RE and increase TLR9 expression and consequently the 
number of receptor molecules. Upon TLR9 activation, these cells will produce abnormally high concentrations of IL-
6, resulting in a loop of signal amplification that leads to a deregulation in cell activation and proliferation. 
 
 
We have shown that the presence of allele C at position -1237 alters the transcriptional 
regulation of the TLR9 gene and that binding of the IL-6 RE-BP transcription factor up-regulates 
TLR9 promoter activity, suggesting a pivotal role for IL-6 in the mechanism underlying increased 
susceptibility to NHL. In fact, IL-6 is known to activate signal transducer and activator of 
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transcription 3 (STAT3) (Akira et al., 1994), whose constitutive activation is observed in many 
types of tumours, promoting cell survival and proliferation (Haura et al., 2005). Our results 
showed that cells harbouring the C allele, presumably expressing more TLR9 molecules than its 
wild-type counterpart, also proliferated more in response to the receptor activation. These results 
suggest that a constant activation of TLR9 by persistent ligand binding, such as that occurring in 
chronic inflammatory diseases, could lead to increased proliferation rates of B lymphocytes. This 
proliferation would be considerably amplified in individuals carrying the mutant allele, a premise 
also supported by the fact that the aforementioned persistent infections would lead to increased 
levels of circulating IL-6, thus resulting in augmented TLR9 expression and ultimately increased 
amounts of receptor molecules. On the other hand, TLR9 activation in B lymphocytes, especially 
those harbouring the C allele, leads to increased release of IL-6, thus adding up to the effect and 
promoting a loop of signal amplification. The exacerbated cellular proliferation resulting from 
chronic immune stimulation by TLR9 ligands would eventually make B lymphocytes more 
susceptible to acquire transforming mutations, such as bcl-2 translocations or mutations affecting 
the c-myc gene (Ivanovski et al., 1998; Pagano, 2002; Staak et al., 2002). 
The neoplastic process leading to the development of NHL may be usurping impairments 
in TLR signalling pathways to advance cancer progression, which suggests that targeting these 
pathways may open novel therapeutic avenues. CpG oligodeoxynucleotides (ODNs) are now 
regarded as highly promising for the use in cancer therapy, mostly due to the direct effect of 
TLR9 activation on immune cell subpopulations that play an important role in anti-tumour 
immunity, including B cells (Krieg et al., 1995). CpG ODNs are also known to induce enhanced 
production of a number of cytokines with anti-tumour activity, including TNF, IL-12 and IFN-γ 
(Lipford et al., 1997). However, therapeutic applications of these CpG ODNs should be 
individually tailored since, as shown in the present study, individual variations can affect the 
outcome of the TLR9 signalling pathway. Our results showed that simultaneous stimulation of 
cells harbouring the mutant allele of T-1237C with both CpG ODN and CpG TTAGGG, a known 
TLR9 antagonist, reverted the elevated proliferation rates displayed by these cells when solely 
stimulated with CpG ODN. In this sense, our results not only discard the use of stimulatory CpG 
ODNs in this particular subset of NHL patients, but suggest a potential application of TLR9 
antagonists in the suppression of the uncontrolled cellular proliferation that may be underlying 
the NHL risk in patients harbouring the mutant allele of T-1237C. 
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In many chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus 
erythematosus, IL-6 signalling is critically involved in the maintenance of a disease state by 
promoting transition from acute to chronic inflammation (Rose-John et al., 2006), which often 
correlates with the development of NHL. Accordingly, our results have shown that IL-6 also plays 
a crucial role in the increased TLR9 expression exhibited by cells carrying the mutant allele of T-
1237C. However, the resulting increased proliferation can be abrogated by the use of a 
neutralizing anti-IL-6 antibody, which similarly to CpG TTAGGG, is able to suppress proliferation 
after TLR9 stimulation to values close to those displayed by the wild-type cells. This, as occurred 
for the TLR9 antagonist, suggests a potential application of anti-IL-6 antibodies in controlling not 
only inflammation but aberrant proliferation, at least in this particular scenario. 
In conclusion, our study demonstrates an association between the T-1237C 
polymorphism and susceptibility to NHL and suggests that increased B lymphocyte proliferation 
resulting from an amplified TLR9 expression due to an IL-6-dependent trans-activation may be 
involved in the mechanism underlying individual susceptibility to the development of this 
particular lymphoproliferative malignancy. 
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Fungi are ubiquitous organisms in the environment that are constantly interacting with 
the human host. Despite their abundance and widespread distribution, most of the fungal species 
do not trigger disease in healthy individuals; however some act as opportunistic pathogens in 
individuals with specific immune defects. Invasive, life-threatening fungal infections are 
undoubtedly the most important group of fungal infections, whose vast majority is attributable to 
Candida and Aspergillus species. The incidence of these infections has risen in the past years 
mostly due to advanced medical and surgical interventions that compromise patient immunity, 
including immunosuppressive therapy producing prolonged neutropenia, such as that occurring 
in stem cell or solid-organ transplanted patients (Fridkin and Jarvis, 1996). In addition, despite 
the development and availability of new antifungal drugs, invasive fungal infections, in particular 
those affecting immunocompromised patients, still present high morbidity and mortality rates 
(Wenzel and Edmond, 2001) often due to late and inaccurate diagnosis. These limitations in 
diagnosis often hamper the application of proper and timely antifungal therapy. In fact, several 
studies have pointed out that early and accurate diagnosis, together with the subsequent early 
initiation of therapy improves the outcome of the disease (Barnes, 2008). Additionally, the use of 
antifungal prophylactic strategies in patients most at risk of these infections is resulting in the 
emergence of fungal pathogens with an increased resistance to the drugs commonly available; 
newly emerging fungal species include not only species of Candida other than C. albicans, but 
also Aspergillus spp. and other filamentous fungi. In that sense, optimal patient management will 
require not only the development of new diagnosis strategies able to cope with the current 
limitations of the available methodologies, but also the identification of high-risk groups in which 
the prevalence of fungal infection is known to be increased. 
This dissertation was developed within the abovementioned problematic, envisaging that 
necessary investigations in this field including the development of accurate and rapid diagnostic 
methods, and that a step forward could be given in risk stratification with the identification of 
human genetic susceptibility markers allowing identification of patients most at risk. 
Accurate and timely diagnosis of fungal infections remains a problematic issue regarding 
immunocompromised patients, in whom signs and symptoms are non-specific and often develop 
late in the course of infection. Even though C. albicans is still the most common and clinically 
relevant fungal pathogen, other species, often resistant to the currently available antifungal 
agents, have been recently emerging. These observations led both researchers and clinicians to 
an intensive development of alternative diagnostic methods in recent years allowing identification 
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of Candida to the species level. In this sense, we developed a multiplex PCR-based method with a 
test matrix able to identify eight of the most clinically relevant Candida species, namely C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, C. lusitaniae and 
C. dubliniensis (Chapter 2). The designed diagnostic method allows the identification of yeasts 
that have non-standard morphologic, cultural and biochemical characteristics with high 
specificity, devoid of interference by other microorganisms that commonly co-infect 
immunocompromised patients. Additionally, under laboratory conditions, using artificially seeded 
blood, the method revealed a high sensitivity, allowing the identification of approximately 2 
live/intact Candida cells per ml of blood. This attribute, together with the reduced time required 
for identification to a minimum of 5 hours, will allow clinicians to detect candidaemia in its early 
stages of development, where few circulating Candida cells are present. Altogether, these 
features point to a highly advantageous application in the detection and identification of Candida 
species in both clinical diagnosis and epidemiological studies, although validation in clinical 
settings is still required. 
As referred above, and despite common immunosuppression, not all patients develop 
fungal disease, thus suggesting that in addition to characteristic traits of the fungi involved, 
individual genetic variations may contribute to their onset. Recently, considerable attention has 
been given to variations in genes of the innate immune response such as Toll-like receptors 
(TLRs) and their potential association with susceptibility to infectious disease (Schroder and 
Schumann, 2005). In the same way, these variations could underlie an increased predisposition 
to infections of fungal nature, both invasive as well as non-invasive. Recently, extensive research 
coverage has been given to association studies between the presence of single nucleotide 
polymorphisms (SNPs) and differences in susceptibility to diseases of diverse aetiologies, both 
infectious and non-infectious. The fact that most of the methods currently available to assess 
polymorphisms are either time-consuming or laborious, requiring expensive equipment, led us to 
adapt a simple and rapid method, allowing genotype determination in a single PCR reaction 
(Chapter 3). Accordingly, genotyping of TLR polymorphisms performed in the association studies 
depicted in Chapters 4, 5 and 6 was carried out using this methodology. Moreover, the work 
developed in Chapter 3 illustrates, to the best of our knowledge, the first characterization of the 
general Portuguese population regarding polymorphisms in TLRs. The allele frequencies of the 
different studied polymorphisms did not significantly differ from those described in the literature 
for other Caucasian populations (Vogel et al., 2005). The results presented can be of further use 
  101
in association studies for different disorders in the Portuguese population. Also, taking into 
account the role of these polymorphisms and susceptibility to infectious disease, the data 
presented provides valuable information that can be potentially used to stratify patients most at 
risk regarding infection as highlighted in Chapters 4, 5 and 6. 
As previously stated, the role of TLRs in the recognition of pathogenic fungi and the 
initiation of the inflammatory response led us to raise the hypothesis that individuals carrying 
polymorphisms in TLR genes could display differential levels of protection against fungal 
infection. Although in the beginning of this dissertation project, we intended to study how the 
genetic background, particularly regarding TLR genes, could contribute to both infections with 
Candida and Aspergillus species, mostly due to sample limitations, the developed work focused 
primarily in susceptibility to different forms of aspergillosis. TLR4 has always displayed an 
intriguing role in the recognition and initiation of the inflammatory response to Aspergillus. 
Experimental evidence indicates TLR4 as one of the most important innate immune pathways in 
response to the fungus (Bellocchio et al., 2004a; Braedel et al., 2004; Chignard et al., 2007; 
Mambula et al., 2002; Netea et al., 2003). Accordingly, we found that a TLR4 polymorphism - 
Asp299Gly - was highly associated with the development of a non-invasive form of pulmonary 
aspergillosis, chronic cavitary pulmonary aspergillosis (CCPA) (Chapter 4). Furthermore, we 
found a positive association between the same SNP and fungal colonization but not susceptibility 
to fungal infection in haematopoietic stem cell transplanted (HSCT) patients (Chapter 5). These 
results suggest that the failure to recognize the fungus due to a defective TLR4 extracellular 
domain may be predisposing to fungal colonization, in the same way it occurred for CCPA. 
However, this effect may be compensated by the lack of an enhanced inflammatory response to 
the fungus due to impairment in the production of proinflammatory cytokines, thus contributing 
to fungal infection resistance. Despite a comprehensive knowledge on TLR4 polymorphisms and 
susceptibility to infectious and non-infectious diseases, their role in the standard performance of 
the immune system is still obscure. Thus, since Asp299Gly appears to be essential in the 
outcome of the host-Aspergillus interaction, functional studies regarding the impact of this 
polymorphism on TLR signalling pathways are imperative. For such, the evaluation of the 
cytokine profile triggered by Aspergillus species in human cell lines carrying Asp299Gly could 
shed light in the mechanism underlying the genetic associations herein presented. In addition, 
the modulation of gene expression of other TLRs, namely TLR2, in association with the different 
TLR4 genotypes, could give further insights on the balance of the Th1/Th2 types of response 
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regarding the relationship between local colonization and disseminated infection. Overall, 
functional studies regarding the impact of this polymorphism on TLR signalling pathways will 
allow the design of new targeted antifungal therapeutics taking into consideration the TLR4 
genotype of each individual. 
On the other hand, the TLR9 polymorphism T-1237C, previously linked to an increased 
predisposition to several diseases of chronic inflammatory nature, was shown to be associated 
with susceptibility to both ABPA (Chapter 4) and viral infection (Chapter 5). Thus, taking into 
account the critical role of TLR9 in viral sensing, assuring rapid antiviral responses, as well as in 
the control of allergy to fungi, a putative disease mechanism involving this polymorphism would 
be an exuberant inflammatory response due to increased TLR9 expression levels and 
concomitant receptor stimulation. Accordingly, a shared disease mechanism was also proposed 
as a risk factor for developing non-Hodgkin lymphoma (NHL) (Chapter 6). The presence of the T-
1237C polymorphism was shown to introduce a new regulatory sequence in the TLR9 promoter, 
trans-activated by an IL-6-dependent transcription factor, ultimately resulting in increased TLR9 
expression. This effect, together with persistent receptor activation, was shown to lead to 
increased B lymphocyte proliferation and augmented IL-6 production by these cells harbouring 
the mutant allele, ensuing cell-specific uncontrolled proliferation (Chapter 6). These abnormally 
high proliferation indexes can make cells more prone to the acquisition of specific transforming 
mutations leading to the development of NHL, such as those occurring in the bcl-2 or c-myc 
genes. Furthermore, the use of blocking agents of the pathways involved in this disease 
mechanism, such as neutralizing anti-IL-6 antibodies or TLR9 antagonists that limit the outcome 
of its signal transduction pathway, was shown to inhibit the pronounced effects of the 
polymorphism on gene expression, proliferation and IL-6 production. The proposed susceptibility 
model, as well as the suggested targeted therapeutics, namely the use of anti-IL6 antibodies or 
TLR9 antagonists, requires future confirmation in NHL patients. In addition, the recent use of 
CpG agonists in the treatment of cancer and autoimmune diseases should be seen with 
moderate distrust, as individual variations affecting the outcome of the TLR9 signalling pathway 
suggest the requirement of individual tailored CpG-based treatments depending on the TLR9 
genotype. 
The results and considerations presented throughout this dissertation reinforce the 
requirement for changes in the management of fungal infections. First, at the fungus level, with 
the development of better diagnostic procedures ensuing proper and timely establishment of 
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antifungal therapy that can potentially contribute to a reduction in the high mortality rates 
associated to these diseases. Second, at the host level, with the understanding of the impact of 
individual genetic variations in the outcome of the host-fungi interaction that may allow 
stratification of patients most at risk of infection and the use of alternative therapeutic strategies. 
These conclusions reinforce the need for future studies elucidating the effect of TLR 
polymorphisms both at molecular and cellular level. More specifically, the characterization of the 
balance between Th1/Th2 cytokine profiles resulting from the stimulation of defective TLRs 
should be elucidated in the future, allowing the clarification of the impact of these polymorphisms 
in immune cell function and activation of the adaptive immune response in in vitro models of 
infectious disease. This will allow the description of functional models depicting the correlation 
between the discovered functional alterations and susceptibility to infectious diseases, thus 
identifying therapeutic targets and/or strategies able to exert control over TLR signalling pathways 
and thus minimize the defects in cell function underlined by the polymorphisms. 
In summary, the information presented in this dissertation further highlights the 
importance of TLR polymorphisms in susceptibility/resistance to fungal infections, both in its 
invasive and non-invasive forms. Additionally, the shared mechanisms affected by TLR 
polymorphisms may predispose to diseases of variable aetiology, as was shown for T-1237C and 
NHL. Altogether, the information regarding individual predisposing variants may potentially be 
used in the future, allowing the formulation of individually tailored therapeutic approaches. 
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